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ABSTRACT
Cyclic 3',5'-guanosine monophosphate (cGMP) is a key signaling molecule
involved in a myriad of physiological processes, including vascular smooth muscle
(VSM) tone, water- and electrolyte homeostasis, platelet aggregation, airway smooth
muscle tone, smooth muscle proliferation and bone formation. Increased occurrence of
vascular disorders including erectile dysfunction, hypertension, stroke and coronary
artery disease, have made it increasingly important to study the dynamic interplay
between cGMP synthesis and hydrolysis in VSM cells. This dissertation examines the
spatial distribution of intracellular cGMP, [cGMP]i, in response to NO and atrial
natriuretic peptide (ANP) in VSM cells. To investigate the spatial patterning of [cGMP]i,
we have developed a new generation of non-FRET (fluorescence resonance energy
transfer) cGMP biosensors that are suitable to monitor [cGMP]i in response to
physiological (low-nanomolar) NO and ANP concentrations and that qualify for realtime, confocal imaging techniques. We have termed these indicators FlincGs, for green
fluorescent indicators of cGMP. For the development of FlincGs, we made use of the
specific cGMP binding characteristics of PKG. We utilized site-specific mutagenesis,
kinetic cGMP binding, dissociation and kinase assays, as well as crystallography, in order
to investigate PKG activation and cGMP binding dynamics in greater detail. Based on
these studies, our novel, non-FRET cGMP biosensors were designed by attaching cGMP
binding fragments of PKG to the N-terminus of circular permutated green fluorescent
protein. We applied FlincGs in cultured VSM cells as well as in intact tissue to determine
whether two spatially distinct populations of guanlylyl cyclase (cytosolic versus
membrane bound) underlie the generation of spatiotemporally-specific patterns of
[cGMP]i formation.
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CHAPTER ONE: LITERATURE REVIEW
Introduction
Cyclic 3’,5’-guanosine monophosphate (cGMP) regulates vital physiological
processes through activation of cGMP-dependent protein kinases (PKGs), cyclic
nucleotide gated ion channels and cGMP-specific phoshpodiesterases (PDEs) (Conti and
Beavo, 2007; Francis et al., 2005; Hofmann, 2005; Hofmann et al., 2005), (Figure 1).
cGMP synthesis is mediated either through soluble guanylyl cyclases (sGC) in response
to nitric oxide (NO), or through particulate, membrane bound guanylyl cyclases (GCA/B) in response to natriuretic peptides (ANP, BNP, CNP) (Kuhn, 2005). Intracellular
cGMP concentration, [cGMP]i, is kept in a dynamic balance through guanlylyl cyclases,
that convert guanosine tri-phosphate (GTP) into cGMP and through cGMP-specific
phosphodiesterases, that promote cGMP hydrolysis (Figure 2). cGMP binding to PKGs
promotes phosphorylation of many downstream targets, thereby modulating a multitude
of physiological processes.

(Atrial) Natriuretic Peptide production and release
Natriuretic peptides - atrial natriuretic peptide (ANP), B- and C-type natriuretic
peptites (BNP, CNP) - are derived from arachidonic acid and share a common core
structure consisting of a 17-member disulfide ring with a highly conserved internal
sequence of (-FGXXXDRIGXXSGL-) (Kangawa and Matsuo, 1984; Sudoh et al., 1988;
Sudoh et al., 1990). ANP and BNP are predominantly expressed in cardiac myocytes and
act as antihypertensive and antihypervolemic factors through their actions on GC-A
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expressed in peripheral tissues (such as VSM cells) and in the central nervous system. In
contrast, CNP is mostly produced by vascular endothelial cells and has local effects on
vascular regeneration (Komatsu et al., 1996; Tamura et al., 2004; Yamahara et al., 2003)
and bone growth (Chusho et al., 2001) by binding to the specific membrane-bound
guanylyl cyclase (GC) receptor GC-B (Garbers and Lowe, 1994). Most of our knowledge
about the ANP/GC-A system in maintaining arterial blood pressure and blood volume has
come from different genetic mouse models. Deletion of ANP or its receptor GC-A lead to
arterial hypertension and cardiac hypertrophy (John et al., 1996; Kuhn et al., 2002; Lopez
et al., 1995), whereas overexpression of ANP or GC-A lead to a decrease in arterial blood
pressure (Oliver et al., 1998; Steinhelper et al., 1990).
Main triggers for the release of ANP from atrial secretory granules in cardiac
myocytes are an increase in wall stretch, pressure and ischemia (de Bold et al., 1981; de
Bold et al., 2001), but neurohumoral factors (glucocorticoids, catecholamines, arginine
vasopressin, angiotensin II and endothelin) may also play a role (Ruskoaho, 1992)
(Figure 3). Once in the bloodstream, ANP activates the GC-A receptor in peripheral
tissues to increase [cGMP]i (Garbers and Lowe, 1994) (Figure 1) and thereby modulates
blood pressure and blood volume in an endocrine fashion through vasorelaxation, diuresis
and natriuresis.
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Nitric Oxide synthesis and release
Besides natriuretic peptides, increasing concentrations of [cGMP]i are also
mediated through the action of nitric oxide (NO) on soluble guanylyl cyclases (sGC)
(Figure 1). In vascular endothelial cells, NO is produced by the endothelial nitric oxide
synthase, eNOS (Palmer et al., 1988). Activation of eNOS occurs primarily through
agonist-modulated increases in intracellular calcium, and binding of Ca2+-calmodulin to
eNOS (Figure 4). Endogenous ligands for G-protein coupled receptors that mobilize
calcium and activate eNOS include acetylcholine (which signals via M3 muscarinic
receptors), histamine, adenosine, ATP/ADP, thrombin, and bradykinin (Moncada et al.,
1991). Stimulation of NO-synthesis can also be initiated through shear stress (via
mechanoreceptors) (Gudi et al., 1998), or through phosphorylation and de-nitrosylation
of eNOS (via sphingosine 1-phosphate, VEGF or insulin) (Dimmeler et al., 1999; Erwin
et al., 2005; Kou et al., 2002; Montagnani et al., 2001; Olivera and Spiegel, 1993).
Catalytically active eNOS converts L-Arginine to NO and L-Citrulline. NO is then
released and can freely diffuse into cells. NO has a short half-life of approximately 5 sec
and is buffered in the blood stream through binding to the ferrous heme moiety of
hemoglobin. The physiological effects of NO in the vasculature are mediated through
increased [cGMP]i via sGC and include inhibition of leukocyte adhesion and platelet
aggregation, suppression of smooth muscle cell proliferation and induction of vascular
smooth muscle relaxation, leading to vasodilation (Hofmann, 2005).
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Guanylyl cyclase mediated synthesis of [cGMP]i
Guanine nucleotidyl (guanylyl) cyclases (GCs) are widely distributed signaltransduction enzymes that, in response to NO and natriuretic peptides, convert GTP into
the second messenger cyclic GMP (Figure 2). The diffusible gas NO targets the heme
containing enzyme soluble guanylyl cyclase (sGC), a protein ubiquitously expressed in
mammalian cells. Studies from sGC-deficient mice have shown that NO-sGC signaling is
essential for the maintenance of normal peristalsis in the gut, and for the regulation of
blood pressure and vascular smooth muscle tone (Friebe et al., 2007; Mergia et al., 2006;
Nimmegeers et al., 2007). sGC is a heterodimeric protein, consisting of a larger alphasubunit and a smaller heme-binding beta-subunit (Figure 5). Four human sGC subunits
exist: α1, α2, β1 and β2, of which the α1/β1 and α2/β1 heterodimers are best characterized
(Mayer and Koesling, 2001; Zabel et al., 1998). The β-subunit contains a conserved
amino-terminal heme-binding domain (Iyer et al., 2003; Pellicena et al., 2004), which is
crucial for NO sensing. NO-induced activation of sGC depends on the presence of the
reduced Fe2+ heme moiety (Ignarro et al., 1986). Binding of NO (10 to 100 nM; (Mo et
al., 2004)) to the central ferrous iron of the prosthetic group induces conformational
changes in the C-terminal catalytic domain, leading to a 400-fold increase in activity of
sGC (Mayer and Koesling, 2001) and to conversion of GTP into cGMP and
pyrophosphate (Figure 2). The catalytic domains of both subunits are required for the
formation of a catalytically active center (Winger and Marletta, 2005). In recent years,
Marletta and colleagues have reported a second NO binding site (Ballou et al., 2002;
Cary et al., 2006; Zhao et al., 1999), suggesting a more complex mechanism of sGC
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activation. sGC activity can be increased through commercially available compounds that
act either as heme-dependent sGC stimulators (YC-1, BAY 41-2272, BAY 41-8543,
CFM-1571 and A-350619) or as heme-independent sGC activators (BAY 58-2667 and
HMR-1766) (Evgenov et al., 2006; Schindler et al., 2006). Oxidation of sGC inhibits
cyclase activity, and is typically generated through the use of the pharmacological agents
ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), NS2028, methylene blue or
ferricyanide (Hwang et al., 1998; Olesen et al., 1998; Schrammel et al., 1996; Zhao et al.,
2000). Endogenously, changes in the redox state of sGC can be induced by reactive
oxygen and nitrogen species such as superoxide (O2-) and peroxynitrite (ONOO-), which
are generated under conditions of oxidative stress (Stasch et al., 2006). Carbon monoxide
can bind to the sGC heme group, but increases sGC activity only by a factor of 4,
underscoring the requirement for the particular NO-mediated conformational change (Ma
et al., 2007).
In contrast to sGCs, the transmembrane particulate GCs (GC-A and GC-B) serve
as a receptor for atrial, B-type (GC-A) and C-type (GC-B) natriuretic peptides. GC-A/B
possess a variable N-terminal extracellular receptor domain, a transmembrane domain
and an intracellular region consisting of a protein kinase–homology domain (KHD), an
amphipathic alpha-helical or hinge region, and a C-terminal cyclase–homology catalytic
domain (Chinkers and Garbers, 1989; Liu et al., 1997; Wilson and Chinkers, 1995)
(Figure 5). Transmembrane particulate GCs exist as homodimers, and dimerization is
required for full catalytic activity. Binding of natriuretic peptide to the extracellular
receptor domain induces conformational changes that lead to cGMP synthesis in the
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intracellular catalytic domain (Figure 2). The KHD domain modulates the enzyme
activity of the C-terminal catalytic domain (Koller et al., 1992). Although the KHD
domain binds ATP and contains many residues conserved in the catalytic domain of
protein kinases, this domain possesses no intrinsic kinase activity. Catalytic activity of
membrane GC can also be modulated through purine nucleoside analogs (P-site
inhibitors) (Joubert et al., 2007).
Both families of guanylyl cyclases, sGC and GC-A, catalyze the synthesis of
[cGMP]i upon stimulation. Due to their distinct cellular localization - membrane bound
GC-A versus cytosolic sGC - in combination with the hydrolyzing properties of PDEs,
both families of GCs may give rise to distinct pools of [cGMP]i and may differentially
modulate the activity of specific target proteins such as phosphodiesterases, ion channels,
cGMP-dependent protein kinases, and downstream cellular events.

Phosphodiesterase mediated hydrolysis of cGMP
In VSM cells and platelets, the GC-mediated increase in [cGMP]i is held in a
dynamic balance through the hydrolyzing activity of cGMP-specific phosphodiesterases
(PDEs) (Figure 2) (Cawley et al., 2007; Mullershausen et al., 2001). Based on substrate
affinity, selectivity, and regulation mechanisms, PDEs have been grouped into 11
different isoenzymes (Conti and Beavo, 2007; Kass et al., 2007). Of these enzymes,
PDE5, PDE6, and PDE9 are highly selective for cGMP, PDE1, PDE2, and PDE11 have
dual substrate affinity, and PDE3 and PDE10 are cGMP-sensitive but cAMP-selective. In
VSM cells, the primary cGMP-PDEs with known activity are PDE1 and PDE5. PDE1 is
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a calcium/calmodulin-dependent enzyme while PDE5 is the first identified selective
cGMP esterase. PDE3, a cAMP esterase expressed in VSM cells, can be inhibited by
cGMP.
In addition to being hydrolyzed by PDEs, cGMP can modulate the catabolic
activity of these enzymes by binding to tandem regulatory GAF domains, which are
named for the first three classes of proteins found to contain the cGMP-binding sequence:
mammalian cGMP-binding PDEs, Anabaena adenylate cyclase, and Escherichia coli
Fh1A. In the case of PDE5, binding of cGMP to the two GAF sites induces a
conformational change in PDE to activate its catabolic activity and to stimulate cGMP
hydrolysis (Okada and Asakawa, 2002; Rybalkin et al., 2003). PDE1 does not contain
any GAF sites. Another mechanism to modulate PDE activity involves phosphorylation
by PKG. For PDE5, GAF binding promotes phosphorylation through PKG (at 10 x
greater rates than through PKA) (Thomas et al., 1990; Turko et al., 1998). PKG
phosphorylation in turn induces a conformational change that increases the cGMPbinding affinity in the regulatory GAF domain, and enhances cGMP catalytic activity by
50–70% (Corbin et al., 2000). PDE5 may also serve as an intracellular storage site by
allosterically binding cGMP, thus protecting cGMP from hydrolysis and potentially
releasing it when cGMP levels decline due to other signaling events (Gopal et al., 2001).
A third type of functional modulation occurs via cGMP at the catalytic site. PDE3 binds
both cAMP and cGMP at its catalytic site at high affinity. However, cGMP can function
as a competitive inhibitor of PDE3-mediated cAMP hydrolysis (Leroy et al., 1996), and
at low levels of cGMP, the effect is to enhance cAMP and its downstream effects.
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PDE5 has been shown to play a key role in smooth muscle tone, for example in
the corpus cavernosum and the pulmonary vasculature. Protein expression and activity
are also well documented in the cerebellum, stomach, small and large intestine, bladder,
and platelets (Lin et al., 2006). The recent development of highly specific inhibitors such
as sildenafil, tadalafil and vardenafil for PDE5 and vinpocetine for PDE1 has greatly
enhanced our understanding of PDEs. Recent studies in platelets and in aortic tissue have
shown that NO triggers an initial rise and then rapid decline in [cGMP]i (Cawley et al.,
2007; Mullershausen et al., 2001). These studies suggest that auto-activation of PDE5 by
cGMP plays an important feedback role in NO signaling.

cGMP dependent protein kinases (PKGs)
PKG belongs to the family of Ser/Thr protein kinases and transmits changes in
[cGMP]i into downstream signaling events in all eukaryotes (Figure 1). Mammals
uniformly express two PKG genes, prkg1 and prkg2, that encode PKG type I and type II
(Francis and Corbin, 1999; Pfeifer et al., 1999). Two alternatively spliced exons give rise
to the isoforms PKG I α and β that differ only in their N-terminal 90 to 100 residues and
the cGMP concentration required for kinase activation (Ruth et al., 1991).

PKG-Structure and Function
Structurally, the PKG holoenzyme exists as parallel dimer of two identical
subunits, with each subunit possessing an N-terminal dimerization and autoinhibitory
domain, followed by a cGMP binding regulatory domain and a catalytic domain (Figure
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6) (Francis and Corbin, 1999; Pfeifer et al., 1999). PKG homodimers are held together by
a parallel, alpha-helical leucine zipper present in the N terminus (Schnell et al., 2005),
and are targeted to different subcellular localizations by their N-termini via G-kinase
anchoring proteins (GKAPs) (Cha et al., 2005), acetylation or myristoylation
(MacMillan-Crow and Lincoln, 1994; Vaandrager et al., 1997). The regulatory domain
contains two in-tandem cGMP receptor sites, A and B that interact allosterically and bind
cGMP with different affinities. Occupation of both binding sites induces a large change
in secondary structure (Landgraf et al., 1990) to yield a more elongated molecule (RichieJannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). The catalytic domain includes
the Mg2+-ATP- and substrate recognition sites. Binding of cGMP to sites A and B in the
regulatory domain releases the inhibition of the catalytic center by the N-terminal
autoinhibitory/pseudosubstrate site and allows the phosphorylation of Ser/Thr residues in
the N-terminal autophosphorylation site and in target proteins. Other mechanisms of PKG
activation include disulfide formation through hydrogen peroxide or heavy metals
(Burgoyne et al., 2007; Landgraf et al., 1991), proteolytic cleavage of an N-terminal 77amino acid peptide (Landgraf and Hofmann, 1989; Scholten et al., 2007), or
phosphorylation events in the N-terminus (Chu et al., 1998; Smith et al., 1996).

Tissue specific distribution of PKG I (α and β) and PKG II
High concentrations (> 0.1 µM) of PKG I are expressed in all smooth muscle,
platelets, dorsal root ganglia, cerebellum, hippocampus, neuromuscular endplate and
kidney (Geiselhoringer et al., 2004). Lower concentrations have been detected in cardiac
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muscle, vascular endothelium, chondrocytes, osteoclasts and granulocytes. PKG I α is
predominantly expressed in lung, heart, dorsal root ganglia and cerebellum, whereas
hippocampal neurons, olfactory bulb neurons and platelets contain mainly PKG I β. Both
isozymes have been identified in smooth muscle cells of the uterus, blood vessels,
intestines and trachea. PKG II is expressed predominantly in the intestinal mucosa, brain
nuclei, kidney, adrenal cortex, chondrocytes and lung (de Vente et al., 2001; el-Husseini
et al., 1995; Vaandrager et al., 1998; Werner et al., 2004).

Physiological roles of PKG II
Most of our knowledge about the physiological roles of PKG II is derived from
PKG II- deficient mice. These studies have shown that PKG II plays an important role in
secretion as well as other cellular processes. PKG II is highly expressed in enterocytes of
the small intestine, where it activates the cystic fibrosis transmembrane conductance
regulator, thereby increasing Cl- and water secretion (Pfeifer et al., 1996; Vaandrager et
al., 2000). Furthermore, PKG II is essential for natriuretic-peptide/cGMP-mediated
endochondral ossification (Miyazawa et al., 2002) and regulates autonomous bone
growth. Studies with PKG II- deficient mice confirmed that PKG II is also involved in
the regulation of the circadian clock (Tischkau et al., 2003). In addition, deletion of PKG
II resulted in mild neurological defects, such as a moderately enhanced anxiety-like
behavior and a hyposensitivity to acute alcohol intake (Werner et al., 2004).
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Physiological roles of PKG I α and β
In contrast to PKG II, the major physiological roles of PKG I include regulation
of vascular smooth muscle tone, smooth muscle proliferation and platelet aggregation.

Platelet Aggregation
Aggregation of platelets is initiated at areas where the endothelial cell layer has
been destroyed. Endothelial cells release prostacyclin and NO, consequently raising
cAMP and cGMP levels in platelets which thereby prevent clot formation. PKG I is
expressed at high levels in platelets and has an anti-aggregatory function (Gambaryan et
al., 2004; Marshall et al., 2004; Massberg et al., 1999). An intact platelet NO/PKG I
signaling pathway is essential to prevent platelet aggregation after ischemia in vivo
(Massberg et al., 1999). Platelets contain two well established PKG I substrates, VASP
and IRAG. Deletion of the VASP gene in mice did not grossly affect platelet aggregation
(Aszodi et al., 1999; Hauser et al., 1999), but considerably affected the interaction of
platelets with the endothelium in vivo (Massberg et al., 2004). Activation of PKG I
inhibited the release of Ca2+ from IP3-sensitive stores in wild type and VASP-deficient
platelets to similar extents (Aszodi et al., 1999). Furthermore, platelets from the IRAG
mutant mice have a severe defect in the cGMP-mediated prevention of aggregation
indicating that IRAG is an essential component of this pathway (Geiselhoringer et al.,
2004).
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Regulation of Smooth Muscle Proliferation
NO, ANP, and cGMP analogs have been shown to prevent proliferation,
migration, and dedifferentiation of vascular smooth muscle cells (Calderone et al., 1998;
Garg and Hassid, 1989). Recent studies suggest that PKG I modulates gene expression
through the extracellular signal-regulated kinase/mitogen-activated protein kinase
pathway (Hofmann et al., 2000; Pilz and Casteel, 2003). VASP, an actin-binding protein
localized at the focal adhesion and cell-to-cell contacts in many cells, is differentially
phosphorylated by protein kinase C, cAMP kinase, and PKG I, and might be a key player
in this signaling cascade (Chen et al., 2004).

Regulation of vascular smooth muscle tone
In general, smooth muscle tone is regulated by the rise and fall of intracellular
calcium, [Ca2+]i. The rise of [Ca2+]i is initiated either by receptor-mediated generation of
inositol triphosphate (IP3) that releases Ca2+ from intracellular stores or by an influx of
extracellular Ca2+ through voltage-dependent Ca2+ channels (Moosmang et al., 2003).
This rise in [Ca2+]i initiates contraction by activation of the Ca2+/calmodulin-dependent
myosin light chain kinase (MLCK), which phosphorylates the regulatory light chain
(RLC) and, consequently, activates myosin ATPase. A decrease in [Ca2+]i deactivates
MLCK, allowing for dephosphorylation of RLC by myosin light chain phosphatase
(MLCP) (Surks et al., 1999). Smooth muscle contraction is also modulated at constant
[Ca2+]i by changing the sensitivity of the contractile machinery to [Ca2+]i (Somlyo and
Somlyo, 2003). PKG I interferes both with the increase in [Ca2+]i and with the Ca2+
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sensitivity through phosphorylation of IRAG, Ca2+-activated maxi-K+ (BKCa) channels,
phospholamban (Koller et al., 2003; Porter et al., 1998; Robertson et al., 1993) and
MLCP (Figure 1).
One mechanism to lower [Ca2+]i is the PKG I-dependent phosphorylation of
IRAG. IRAG is expressed at the endoplasmic reticulum membrane in smooth muscle,
platelets, and some neurons, and interacts specifically with the leucine zipper of PKG I
and with the IP3 receptor type I (Ammendola et al., 2001; Geiselhoringer et al., 2004).
Studies on IRAG-deficient mice revealed that PKG I-dependent phosphorylation of
IRAG inhibits IP3-induced Ca2+ release (Geiselhoringer et al., 2004). Additionally, PKG I
lowers [Ca2+]i through direct phosphorylation of BKCa channels (Robertson et al., 1993).
Opening of BKCa channels hyperpolarizes the membrane and closes L-type calcium
channels, thereby reducing Ca2+ influx. This mechanism contributes to the regulation of
vascular tone, as shown in wild type and PKG I-deficient mice (Sausbier et al., 2000). An
alternative mechanism to regulate smooth muscle tone is the PKG I dependent
phosphorylation and activation of MLCP (Etter et al., 2001). Consequently, RLC
phosphorylation is reduced and smooth muscle relaxed at constant [Ca2+]i.

Detection of [cGMP]i using fluorescent indicators
cGMP is a key signaling molecule for regulating vascular smooth muscle tone. In
the past, [cGMP]i has been detected utilizing techniques such as guanylyl cyclase assays
(Domino et al., 1991), radio-immunoassays (Brooker et al., 1979), patch cramming
(Trivedi and Kramer, 1998) and patch clamping (Castro et al., 2006). However, the
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dynamic rise and fall of [cGMP]i in living cells could not be monitored directly until the
development of fluorescent cGMP biosensors (Honda et al., 2001; Nikolaev et al., 2006;
Russwurm et al., 2007). In recent years, several fluorescence resonance energy transfer
(FRET) - based indicators for cGMP have been reported, all of which utilize the general
strategy of placing a conformationally sensitive cGMP binding domain between two
mutants of green fluorescent protein (GFP) to modulate FRET. In 2001, Honda and
colleagues were the first to report the successful development of FRET-based cGMP
biosensors, called cygnets, by inserting a kinase inactive deletion fragment of cGMPdependent protein kinase (PKG) between cyan (CFP) and yellow (YFP) mutants of green
fluorescent protein (Honda et al., 2001). cGMP binding to Cygnets decreased FRET and
increased the overall ratio of cyan to yellow emissions by up to 1.5-fold for recombinant
protein. Recombinant cygnets are also highly selective (>100 fold) for cGMP over cAMP
with apparent KD values ranging from 0.6 to 1.9 µM (Honda et al., 2001; Honda et al.,
2005), (Table 1). Cygnets have revealed transient cGMP kinetics resulting from sGC
activation by NO in rat fetal lung fibroblast (RFL)-6 cells, in Purkinje neurons (Honda et
al., 2001) and in cultured, unpassaged rat aortic VSM cells (Cawley et al., 2007). Reports
on the next set of FRET-based cGMP indicators followed in 2006, when isolated
nucleotide binding domains, such as the single cGMP-binding domain B from PKG I or
the single regulatory GAF domain from PDEs, were sandwiched between CFP and YFP
(Nikolaev et al., 2006). These new indicators displayed cGMP affinities in the low
micromolar range (Table 1) and had moderate (100 fold; PKG/PDE2-based) to high (400
to 600 fold; PDE5-based) cGMP selectivity. In HEK cells, the sensors based on a single
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PDE-GAF domain produced maximal 1.3 fold increase in FRET ratio and rapid
responsiveness to NO-induced sGC activation. In 2007, Russwurm and colleagues
reported the latest FRET-cGMP biosensors based on cyclic nucleotide binding sites of
PKG I (Russwurm et al., 2007). Interestingly, only cGMP-binding domains arranged in
tandem configuration as in their native configuration were cGMP-responsive. These new
sensors produced an overall 1.6 to 1.7-fold increase in FRET ratio for recombinant
protein upon cGMP binding, high cGMP affinities (0.5 to 6 µM), high cGMP selectivity
and fast cGMP binding kinetics (Table 1).
While the above mentioned cGMP biosensors have advanced our understanding
of cGMP signaling, they all have some intrinsic limitations. For example, in living cells,
all FRET based cGMP indicators display significantly decreased FRET ratios (maximal
1.3 fold FRET ratio change), possibly due to interactions with endogenous proteins (such
as PKGs and PDEs), as well as unspecific interactions caused by CFP and YFP. Due to
these overall low FRET ratios, FRET-based indicators are not suitable for transgenic
mouse models and hence are limited in their use to follow [cGMP]i dynamics in
physiological systems. Furthermore, FRET-based indicators are unable to detect cGMP
dynamics in response to physiological, low-nanomolar NO concentrations. In addition,
FRET-based cGMP indicators are limited in their use for real-time, confocal imaging
techniques and therefore have limited use to study real-time [cGMP]i dynamics in
microdomains of living cells. These limitations prompted us to develop a new generation
of non-FRET cGMP biosensors (Chapter 4), called FlincGs, suitable to monitor [cGMP]i
in response to physiological (low-nanomolar) NO concentrations. In addition, FlincGs are
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powerful tools to study [cGMP]i dynamics in response to various stimuli, by utilizing
high-resolution, real-time confocal microscopy. FlincG-type biosensors are derived from
the cGMP-receptor domains of PKG. Thus, it has been necessary to characterize the
molecular mechanism and the cGMP binding dynamics underlying PKG activation
(Chapters 2 and 3).

Focus of Dissertation
Regulation of vascular smooth muscle tone is one of the major functions of
cGMP-dependent protein kinase I. To investigate in detail cGMP-dependent PKG
activation, we introduced several site-specific mutations in the regulatory cGMP binding
domain and studied their effects on cGMP binding, dissociation and kinase activity
(Chapter 2). We further attempted to crystallize full-length and deletion fragments of
PKG to gain more insight into PKG structure and function (Chapter 3). Based on these
studies, we developed a new generation of PKG-derived, non-FRET cGMP biosensors to
examine the spatial distribution of [cGMP]i in response to NO and ANP in cultured VSM
cells (Chapter 4) as well as in intact cerebral arteries (Chapter 5). These novel indicators
for cGMP allow for investigation of the complex cross-talk between cGMP and calcium,
and in addition, might be suitable for the development of transgenic mice with tissuespecific expression of cGMP biosensors.
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Table 1: Kinetic characteristics of different cGMP biosensors in vitro and in living cells
EC50, cAMP
[µM]
> 1,000

cGMP/cAMP1

(F/F0)max2

(F/F0)max3

Reference

PKG I α (78-671)

EC50,cGMP
[µM]
1.7

> 600

1.5

1.3

(Honda et al., 2001)

PKG I B-site

5.0

486

97

-

1.3

(Nikolaev et al., 2006)

PDE2A GAF-B site
PDE5A GAF-B site
PKG I α (79-345)
PKG I α (79-336)
PKG I α (79-328)
PKG I α (1-356)
PKG I β (1-372)
PKG I α (77-356)

0.9
1.5
0.5
3
6
0.035
1.1
0.17

115
630
40
31
48

128
420
1140
30
280

1.7
1.7
1.6
1.5
2.1
1.7

1.3
1.3
1.3
1.3
1.3
1.2
1.2
1.7

Sensor

Backbone

Cygnet 2.1
cGESGKIB
cGES-DE2
cGES-DE5
cGi-500
cGi-3000
cGi-6000
α-FlincG
β-FlincG
δ-FlincG

(Russwurm et al., 2007)

(Nausch et al, Chapter 4)

1: Selectivity; 2: determined for recombinant protein; 3: determined in living cells;
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Figure legends:

Figure 1: Overview of cGMP signaling in VSM cells. cGMP is synthesized by soluble
guanylyl cyclases (sGC) in response to nitric oxide (NO), or by particulate, membrane
bound guanylyl cyclases (GC-A/B) in response to natriuretic peptides (ANP, CNP).
Physiological effects of cGMP are mediated through the action of phosphodiesterases
(PDEs) and cGMP dependent protein kinases (PKGs), by phosphorylating IRAG,
phospholamban (PL), myosin light chain phosphatase (MLCP) or Ca2+-activated maxi-K+
(BKCa) channels. Adapted from (Hofmann, 2005).

Figure 2: GTP conversion into cGMP and pyrophosphate (PPi) is catalyzed by guanylyl
cyclases (GC), while cGMP hydrolysis is mediated by phosphodiesterases (PDE).
Chemical structures were created with the program ChemSketch.

Figure 3: Atrial Natriuretic Peptide (ANP) secretion from the atrium. Adapted from
(Dietz, 2005; Gardner et al., 2007; Ruskoaho, 1992).

Figure 4: Nitric Oxide (NO) synthesis and release from vascular endothelium. Adapted
from (Albrecht et al., 2003).

Figure 5: General domain structure of dimeric receptor (rGC) and soluble (sGC) guanylyl
cyclases. The receptor architecture consists of the extracellular domain (BCD),
transmembrane segment (TM), kinase homology domain (KHD), coiled-coil domain
18

(CCD) and guanylyl cyclase domain (GC). The heterodimeric soluble guanylyl cyclase
consists of a heme domain (HD), a CC and a GC domain. Adapted from (Fitzpatrick et
al., 2006).

Figure 6: Domain structure of PKG I α. Inset: The alpha-helical, N-terminal dimerization
region is the only domain for which a structure has been determined (Schnell et al.,
2005).
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Abstract
Binding of cGMP manifests the central allosteric mechanism of activation for the
homo-dimeric cGMP-dependent protein kinase Iα (PKG). The relative contributions of
the two in-tandem cGMP binding sites A and B in the enzyme’s mechanism of activation
are not known, however. Based on homology models derived from cAMP-dependent
protein kinases (PKA), we introduced the loss-of-function mutations G167E, E168G,
R177K and G291E, E292G, R301K in each cGMP binding site A and B, respectively.
Surprisingly, the arginine to lysine mutations (R177K, R301K) retained cGMP binding to
both sites. Their differentially shifted activation constants of 620 nM (site A) and 16 nM
(site B) support a hitherto unknown dominant role of site B in modulating the phenotype
of PKG activation. In accordance to the homology models, the glycine and glutamate
mutations fully blocked cGMP binding to either site A or B. In contrast to PKA however,
both site A loss-of-function mutants (G167E, E168G) were unexpectedly cGMPinsensitive, demonstrating constitutively elevated kinase activities. Equally unanticipated,
the equivalent site B loss-of-function mutants (G291E, E292G), as well as the R301K
mutant, showed intact cGMP-dependency of kinase activity characterized by decreased
cGMP-sensitivities. These findings suggest a) juxtaposed orientation of low and high
affinity cGMP binding sites in PKG Iα, compared to PKA Iα, and b) functional coupling
between cGMP binding site A and the catalytic domain. Taken together, we propose a
previously unrecognized concerted mechanism of PKG I α.
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Introduction
The type Iα/Iβ and type II cGMP dependent protein kinases (PKGs) are members
of the cyclic nucleotide-dependent serine/threonine protein kinases with closest sequence
homologies to the type Iα/Iβ and type IIα/IIβ cyclic AMP dependent protein kinases
(PKAs) (Francis and Corbin, 1994; Pfeifer et al., 1999; Scott, 1991). Although both
kinase sub-families possess regulatory domains that modulate the accessibility of
substrates to the catalytic domain, they differ in key architectural aspects that contribute
to their respective mechanisms of activation. The tetrameric PKA holoenzymes are
composed of two regulatory subunits (R2) associated with two catalytic subunits
(Brostrom et al., 1971; Gill and Garren, 1971; Reimann et al., 1971). The R2 subunits
inhibit kinase activity through the association of their autoinhibitory region with the
catalytic subunit (Brostrom et al., 1971; Erlichman et al., 1973; Kemp et al., 1975; Taylor
and Stafford, 1978). Binding of cAMP to the R2 subunits causes the tetramer to dissociate
and thus releases inhibition of the catalytic subunit. The PKG holoenzymes are composed
differently: they consist of dimers of two identical subunits, with each subunit possessing
a regulatory and catalytic domain (Gill et al., 1976; Lincoln et al., 1977; Monken and
Gill, 1980; Takio et al., 1984). For each monomer, the catalytic and regulatory domains
are located on one polypeptide chain and thus cGMP binding cannot induce dissociation
of the catalytic domain from the holoenzyme.
Another notable characteristic for cyclic nucleotide kinases is their distinct
structural order of high and low affinity cyclic nucleotide binding sites relative to the Nterminus (Doskeland et al., 1987; Ogreid and Doskeland, 1980; Ogreid and Doskeland,
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1981; Ogreid et al., 1983). For PKG I β, the slow nucleotide dissociation site is closer to
the N-terminus than the fast dissociation site (Reed et al., 1996), whereas for PKA I,
PKA II and PKG II, the fast dissociation site is closer to the N-terminus (Bubis and
Taylor, 1987; Corbin and Rannels, 1981; Taylor and Uhler, 2000; Weber et al., 1987;
Woodford et al., 1989). These structural differences between PKA I and PKG I as well as
PKG I and PKG II suggest different mechanisms of activation by cyclic nucleotides.
A number of approaches have been implemented to better understand the
molecular events associated with activation of PKG I. Previous studies using
hydrodynamic and small-angle x-ray scattering techniques have demonstrated that cGMP
binding to the regulatory domain of PKG Iα and β induces substantial conformational
changes (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). However, the
individual contributions of each cGMP-binding site still remain unknown. Our attempt to
address this question is based on mutational studies in PKA that led to the development
of a sequential model of type I α PKA activation (Herberg et al., 1996). Previous reports
have identified six highly conserved aminoacids (Gly199, Glu200, Arg209, Gly323,
Glu324 and Arg333) in the regulatory subunit of PKA I α that were critical for cAMP
binding (Bubis et al., 1988; Neitzel et al., 1991; Ogreid et al., 1988; Steinberg et al.,
1991; Steinberg et al., 1987). It has since been confirmed by X-ray crystallography that
the highly conserved glutamate, glycine and arginine indeed coordinate cAMP in the
regulatory subunit to the 2’-OH of the ribose and to the cyclic phosphate moiety,
respectively (Diller et al., 2001; Su et al., 1995; Zawadzki and Taylor, 2004).
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To gain more insight into the actual cGMP binding mechanism in PKG I α and
the molecular mechanism of kinase activation, we have introduced single point mutations
(G167E, E168G, R177K, G291E, E292G and R301K) and have analyzed their kinetic
characteristics with respect to kinase activity depending on cGMP and substrate, as well
as for cGMP binding and dissociation. These mutants allowed us to gain insight into: (1)
the specific sites of communication between regulatory and catalytic domains of PKG,
(2) conformational changes associated with cGMP binding, (3) greatly expand our
current knowledge about the molecular mechanism of PKG activation and also allude to
(4) fundamental differences in the molecular mechanism of activation between PKG I α
and PKA I α.
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Results:
Allosteric binding site mutants of PKG I α
Aminoacid-sequence alignment of cyclic nucleotide binding sites A and B
revealed two highly conserved regions, FGE…RTA for PKG I α and FGE…RAA for
PKA I α respectively (Figure 1A) (Francis and Corbin, 1994; Weber et al., 1989). Both
sequence motifs flank the cyclic-phosphate binding cassette critical for the riboside
moiety and phosphate-diester recognition (Berman et al., 2005; Diller et al., 2001; Wu et
al., 2004). The charged residues as well as the glycine residue in each binding cassette of
PKA I α were of special interest since alterations of these amino acids led to a complete
loss of cyclic nucleotide binding to that site (Gorman and Steinberg, 1994; Murphy and
Steinberg, 1985; Ogreid et al., 1988; Steinberg et al., 1991; Steinberg et al., 1987).
Further studies have demonstrated that the loss-of-function glycine, glutamate and
arginine mutations in the regulatory subunits RIα and RIIβ were particularly useful to aid
our understanding of the mechanism of PKA activation (Bubis et al., 1988; Dostmann
and Taylor, 1991; Neitzel et al., 1991; Wu et al., 2004; Zawadzki and Taylor, 2004). The
goal of this study was to determine if the glycine, glutamate or arginine residues present
in each of the PKG I α binding site pockets modulate (1) cGMP binding to site A and/or
B of the PKG regulatory domain and (2) cGMP specific activation of the kinase catalytic
domain (Figure 1 B). Therefore in analogy to PKA, we selected the following PKG I α
mutants: G167E, E168G, R177K, G291E, E292G and R301K (Figure 1 A). To assess
their kinetic characteristics, all PKG I α mutant and wildtype proteins were expressed in

43

SF9-cells and purified to apparent homogeneity using cAMP-affinity chromatography
(Figure 1 C; see Methods).

Stoichiometry of PKG I α cGMP-binding site mutants
First, we conducted binding studies using [3H]-labeled cGMP (Doskeland and
Ogreid, 1988; Dostmann et al., 1996; Ogreid and Doskeland, 1981) to determine the
influence of the point mutations on the overall cGMP binding capacity (Figure 1 D; Table
1). Replacement of either glycine or glutamate residues in site A (G167E, E168G) or site
B (G291E, E292G) was sufficient to reduce the stoichiometry of cGMP binding to one
ligand per PKG regulatory domain. In contrast to the type Iα regulatory subunit of PKA,
the arginine to lysine mutants (R177K and R301K) fully retained cGMP binding to both
sites A and B (Figure 1 D and Table 1).
To verify the reduced cGMP binding capacity in the glutamate to glycine mutants
(E168G, E292G), we utilized electrospray ionization mass spectrometry (ESI) under nondenaturing conditions (Figures 2 A-F). In agreement with previously published reports,
PKG wildtype gave rise to intense charge state distribution ranging from 23+ to 29+ and
yielding a mass charge envelope of 5,000 to 6,500 m/z (Pinkse et al., 2004; Scholten et
al., 2007) (Figure 2 A). Deconvolution spectra indicate that dimeric native PKG bound in
average two molecules cyclic nucleotides (Figure 2 A, inset), and possibly residual
cAMP from eluting the protein from affinity column or cyclic nucleotides endogenously
present in SF9 cells. Incubation of wildtype PKG with cGMP (20 µM) predicts binding
of four cGMP molecules per dimeric wildtype PKG (measured mass 154.3 kDa) in
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accordance to the number of expected nucleotide binding sites in the dimeric kinase PKG
(Figure 2 B). Both PKG mutants E168G and E292G co-eluted with other (unidentified)
proteins from the affinity columns, however, both PKG mutants gave rise to charge state
distributions of sufficient intensities and qualities to observe and analyze distinct PKG
species (Figures 2 C to F). Deconvolution of the complex charge state distribution of
PKG E292G indicated the presence of dimeric PKG E292G with no cyclic nucleotide,
one and two cyclic nucleotides with approximate contributions of 20%, 38% and 42%,
respectively, as estimated from the deconvoluted mass spectrum (Figure 2 C, inset).
Incubation with 20 µM cGMP gave rise to a stoichiometry of two cGMP molecules per
dimeric PKG E292G (with a measured mass of 153.6 kDa) (Figure 2 D). A minor
fraction (< 20%) of E292G dimer containing three cGMP (measured mass 153.9 kDa)
was also observed. Similarly, nano-electrospray mass spectrometry revealed dimeric
PKG E168G bound to one or two residual cyclic nucleotides (15 and 85 % contribution,
respectively), (Figure 2 E). After incubation with 20 µM cGMP, the predominating
species observed were again dimeric E168G bound to two or three cyclic nucleotides
(with contribution of 80-85 % and 15-20 %, respectively), (Figure 2 F). Therefore, ESI
mass spectrometry supports the [3H]-cGMP binding assays suggesting loss of cGMP
binding in the mutated cGMP binding sites (E168G, E292G).

Kinetic characterization of site A loss-of-function mutants of PKG I α
To gain insight into specific cGMP binding sites of PKG I α, all identified single
site binding mutants (G167E, E168G, G291E, E292G) were tested for their cGMP

45

binding, dissociation and activation kinetics. First, we studied the kinetic behavior of the
N-terminal binding site A mutants G167E and E168G (Figure 3). In contrast to PKG
wildtype (KD = 40 nM), both PKG mutants displayed increased cGMP binding constants
(KD) of 385 nM and 195 nM for G167E and E168G, respectively (Figure 3 A; Table 1).
Skatchard analysis confirmed binding of a single cGMP molecule to the functional, low
affinity site B (KD = 327 nM and 197 nM for G167E and E168G, respectively; Table 1;
Figure 3 B). Based on their Hill coefficients, G167E (nH = 0.6) and E168G (nH = 0.8)
exhibited non-cooperative cGMP binding behavior, further indicating the presence of a
single cGMP binding site in both mutants. In contrast, PKG wildtype displayed highly
cooperative cGMP binding (nH = 1.5), indicating positive cooperativity and cross-talk
between sites A and B under native conditions, as reported previously (Wolfe et al.,
1989). In agreement with cGMP binding studies, cGMP dissociation kinetics attested
monophasic, fast dissociation from the isolated, cGMP binding site B in G167E and
E168G (k-1 = 11.8 and 22.2 min-1, respectively; Table 2; Figures 3 D, E). Dissociation as
well as binding assays confirmed impaired cGMP binding to site A, and intact cGMP
binding to site B, thereby identifying site A as high affinity, and site B as low affinity
binding sites in PKG I α. Surprisingly, kinase activation of mutants G167E and E168G
did not reveal higher activation constants Ka, indicative of lower cGMP binding affinity
(Figure 3 F, Table 3). Instead, site A knock-out mutants exhibited basal, cGMPindependent catalytic activity (10 to 20 %; Figure 3 F) but could not be fully activated in
presence of increasing cGMP concentrations. Therefore, glycine 167 and glutamate 168
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are not only critical for cGMP binding to site A but also reveal that cGMP binding to a
functional cGMP binding site A is essential for kinase activation (Figure 3 G).

Kinetic characterization of site B loss-of-function mutants of PKG I α
Next, we investigated cGMP binding, dissociation and kinase activity of the Cterminal, low affinity binding site B mutants G291E and E292G (Figure 4). Replacement
of glycine 291 or glutamate 292 led to monophasic, non-cooperative cGMP binding with
slightly lower KD-values of 26 nM and 18 nM for G291E and E292G, respectively,
compared to PKG wildtype (Table 1; Figure 4 A). Skatchard analysis confirmed binding
of a single cGMP molecule to the functional high affinity site A (KD = 29 nM and 21 nM
for G291E and E292G, respectively; Table 1; Figure 4 B). Similar to site A knock-out
mutants, Hill coefficients for G291E (nH = 0.9) and E292G (nH = 0.9) indicated noncooperative cGMP binding (Figure 4 C). In addition, cGMP dissociation kinetics verified
slow, monophasic dissociation from site A for mutants G291E (k-1 = 0.01 min-1; τ1/2 = 80
min) and E292G (k-1 = 0.01 min-1; τ1/2 = 90 min) (Table 2; Figures 4 D, E). In agreement
with site A knock-out mutants (Figure 3), dissociation and association kinetics of site B
knock-out mutants confirm that site A and B are high- and low- affinity binding sites for
cGMP, respectively. In contrast to site A knock-out mutants, site B mutants clearly
demonstrated cGMP-dependent activation (Figure 4 F) with maximal kinase activity
comparable to wildtype PKG. However, apparent activation constants (Ka) revealed that
mutants G291E (Ka = 18 nM) and E292G (Ka = 37 nM) bound cGMP with an even
higher affinity than wildtype (Ka = 53 nM), reflecting cGMP binding and kinase
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activation through the higher affinity, intact site A (Figure 4 G, Table 3). Hence, glycine
291 and glutamate 292 are critical for cGMP binding to site B (Figure 4 G), but cGMP
binding to site B is not essential for PKG activation. In the absence of cooperativity,
cGMP binding to a functional site A is sufficient and promotes full PKG activation.
To further investigate the cross-talk between regulatory and catalytic domains of
PKG I α, we tested the PKG mutants E168G and E292G for maximal catalytic activity
depending on substrate concentration and for Michaelis-Menten constants (KM) in
comparison to PKG wildtype catalytic activity (Figure 5, Table 3). When probing E168G
for catalytic activity depending on substrate concentration, this mutant showed an overall
decreased reaction velocity (vmax = 3 ± 0.2 µmol/(mg x min)) and KM value (310 ± 5 nM)
as compared to wildtype (KM = 705 ± 20 nM) (Table 3). In contrast, impaired cGMP
binding to site B had no influence on catalytic velocity, since E292G showed KM (968 ±
26 nM) and vmax values (vmax = 8.9 ± 0.3 µmol/(mg x min)) similar to wildtype PKG I α
(vmax = 10.5 ± 0.4 µmol/(mg x min)). These findings further support our hypothesis that a
dysfunctional site A directly impacts kinase fidelity, thus a fully functional cGMPbinding site A appears to be vital for full PKG activity and seemingly independent of the
cGMP binding site B.

Kinetic characterization of R301K and R177K mutants of PKG I α
Next, we studied the kinetic behavior of PKG mutants R177K and R301K (Figure
6). In contrast to previous studies utilizing PKA (Bubis et al., 1988; Zawadzki and
Taylor, 2004), both arginine to lysine mutants fully retained cGMP binding to both sites
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A and B (Figures 2 A, 6 A). Despite full cGMP binding capacity, R177K and R301K
displayed slightly shifted cGMP activation (Figure 6 A) and binding constants (Figure 6
B) towards higher (R301K) and lower (R177K) cGMP affinity as compared to PKG
wildtype (Tables 1 and 3). This suggests that the arginine to lysine mutations modulate,
but not diminish, cGMP binding to the mutated cGMP binding site. Hill analysis revealed
diminished cGMP-cooperativity (nH = 1.1) as compared to PKG wildtype (nH = 1.5),
indicating that the communication between sites A and B is impaired (Figure 6 C; Table
1). In agreement with kinase activation and cGMP binding studies, cGMP dissociation
kinetics attested biphasic dissociation for both mutants (Figures 6 D; Table 2).
Dissociation kinetics were faster as compared to wildtype and might be a reflection of
reduced cooperativity between cGMP binding sites A and B. These results suggest that
both sites A and B need to be functional and cooperative, in order to achieve cGMP
binding and kinase activation as seen under native, wildtype conditions.
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Discussion:
In the past, extensive mutational analysis has helped to identify six highly
conserved aminoacids (Gly199, Glu200, Arg209, Gly323, Glu324 and Arg333) in the
regulatory subunit of PKA I α that were critical for cAMP binding (Bubis et al., 1988;
Ogreid et al., 1988; Steinberg et al., 1991; Steinberg et al., 1987). It has since been
confirmed by X-ray crystallography that the highly conserved glutamate, glycine,
arginine indeed coordinate cAMP in the regulatory subunit with hydrogen bonds (Su et
al., 1995; Zawadzki and Taylor, 2004). In PKA I α, glutamate 200 has been shown to
coordinate the ribosyl-hydroxy-group of cAMP in the regulatory subunit. Furthermore,
arginine 209 has been identified to stabilize cAMP by interacting with the negatively
charged, axial oxygen of the cAMP-phosphate group (Dostmann and Taylor, 1991;
Dostmann et al., 1990; Su et al., 1995). In our studies, however, only the homologous
glutamate (E168, E292), but not the arginine (R177, R301), was crucial for cGMP
binding to the regulatory domain of PKG I α. Both site A and B knock-out mutants
(E168G, E292G) in PKG I α confirm that the highly conserved glutamate is essential for
cGMP binding. Replacement of glycine (G167, G291) with glutamate might interfere
with cGMP binding due to charge-repulsion caused by the sterically large, charged
glutamate, and therefore, conclusions about glycine-cGMP interactions cannot be drawn.
In this study, abolishing cGMP binding to site A or site B has proven to be an invaluable
tool to gain insight into the molecular mechanism of PKG activation.
For site A knock out mutants, cGMP binding to lower affinity site B is still
functional but not sufficient to fully activate PKG I α (Figures 3 and 7 A). This suggests
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that coupling between a functional site A and the catalytic domain (A-C coupling) is
necessary to fully activate PKG. Site B knock-out mutations further support the
hypothesis, that the catalytic domain is activated directly through site A (Figure 4 and 7
B). In absence of a functional site B, cGMP binding to site A leads to A-C coupling and
to full PKG activation. Besides A-C coupling, the interactions between cGMP binding
sites A and B also play a crucial part in PKG activation. Loss of binding to either one of
the cGMP binding sites consequentially results in loss of cooperativity, as shown by Hill
analysis (Table 1). Due to lack of cooperativity, activation and binding curves for site B
knock-out mutants are shifted towards higher affinities, reflecting the influence of only
one cGMP site, the high affinity site A. The modulatory influence of site B on site A is
lost, and therefore, activation and binding constants are very similar and shifted towards
higher affinities for site B knock-out mutants (e.g. for E291G: Ka = 18 nM; KD = 26 nM)
(Tables 1 and 3). In contrast, the activation constant (Ka = 53 nM) for PKG wildtype
represents a combination of binding constants for both sites A and B and is significantly
higher than the binding constant for PKG wildtype site A (KD = 6/110 nM for site A/B;
Table 1; (Hofmann et al., 1985)), indicating the modulatory effect of site B on site A. The
un-coupling of both cGMP binding sites G291E and E292G allows kinase activation
through site A, since the modulatory (negative) influence of site B on site A is lost.
Based on these results, we present the following mechanism of activation for
PKG wildtype (Figure 7 C): both cGMP binding sites A and B are equally accessible to
bind cGMP. At low cGMP concentrations, site A is fully occupied (KD = 6 nM; Table 1),
but site B (KD = 110 nM; Table 1) prevents site A from activating the catalytic domain
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(A-C coupling interrupted) due to cooperative, (negative-) modulatory effects (nH = 1.5;
Table 1). Only when both sites A and B are fully occupied with cGMP, site A can
communicate to the catalytic domain and initiate the release of the autoinhibitory domain,
hence making the catalytic domain accessible for substrates (Figure 7 C).
Several conclusions can be drawn from the proposed concerted mechanism of
PKG activation: this activation mechanism reveals that site B plays a pivotal role in
modulating responsiveness of PKG to a broader range of [cGMP]i. Therefore, the
mechanism for PKG activation might have developed during evolution in order to allow
PKG to react in response to raising [cGMP]i levels and not to basal cGMP levels in cells
(Francis et al., 1988; Kotera et al., 2003). In addition, the concerted mechanism of
activation for PKG is significantly different from the sequential mechanism of PKA
activation. Biochemical data as well as the recently published crystal structure of PKA
holoenzyme propose a highly ordered and sequential pathway of cAMP binding to the
type I α PKA holoenzyme in which domain B serves as a ‘‘gatekeeper’’ for cAMP access
to domain A (Herberg et al., 1996; Kim et al., 2007; Kim et al., 2005).
Besides being very useful tools to decipher the mechanism of PKG activation, site
A and B knock-out mutants also determine for the first time the distinct structural order
of fast and slow cyclic nucleotide binding sites relative to the NH2 terminus in PKG I α.
For PKG I β, the slow nucleotide dissociation site is closer to the NH2 terminus than the
fast dissociation site (Reed, RB, Corbin JD JBC 1996), whereas for PKA I and PKG II,
the fast dissociation site is closer to the NH2 terminus (Bubis and Taylor, 1987; Corbin
and Rannels, 1981; Taylor and Uhler, 2000; Weber et al., 1987; Woodford et al., 1989).
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Similar to PKG I β, the slow nucleotide dissociation site is closer to the NH2 terminus
than the fast dissociation site for PKG I α.
In conclusion, our data suggest an overall concerted mechanism of activation for
PKG I α that is significantly different from the sequential mechanism of PKA activation
(Kim et al., 2007; Kim et al., 2005). Our results support coupling between both cGMP
binding sites A and B, as well as coupling between cGMP binding site A and the catalytic
domain. Furthermore, the structural order of high and low affinity binding sites for PKG I
α is similar to PKG I β, since the high affinity binding site A is closer to the NH2
terminus. Structural insights into PKG would greatly advance our understanding of
cGMP coordination in the regulatory domain and the complexity involved in kinase
activation.
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Methods
Mutagenesis, expression and purification
cGMP-binding mutants were constructed by introducing single site specific mutations in
the regulatory domain of bovine PKG I α at positions G167E, E168G, R177K, G291E,
E292G and R301K. PKG constructs were preceded by a BamHI site and a start codon
(ATG), and followed by a stop codon and an EcoRI site. The entire PKG coding
sequences were inserted into the BamHI and EcoRI sites of pFAST-BAC vector
(invitrogen) and transected into SF9 cells for expression.
PKG wildtype and mutants were expressed in SF9 cells using the Bac-to-Bac system and
purified utilizing cyclic nucleotide affinity chromatography as described previously (Feil
et al., 1993).

Kinase activity
KM and vmax values were determined according to Ruth and colleagues (Ruth et al., 1991)
by measuring the kinase activity for 1.5 min at 30°C in a final volume of 100 µl
containing 20 µl buffer (250 mM MES pH 6.9; 2 mM EGTA; 5 mM Mg-Acetate; 50 mM
NaCl), 10 µl BSA (10 mg/ml); 10 µl DTT (100 mM); 10 µl [γ-32P] ATP (1 mM; specific
activity 300-400 cpm/pmol), 10 µl cGMP (1 mM) or water, 10 µl appropriate peptide
solution, and 20 µl PKG (5 mM MES, pH 7.0; 0.2 mM EDTA; 0.5 mg/ml BSA) to a final
concentration of 2.6 nM. Fifty five-microliter aliquots were spotted on 2 x 2 cm phosphocellulose paper strips (P-81 Whatman), extensively washed in 75 mM phosphoric acid,
and

the

dried

strips

were

subjected
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to

scintillation

counting.

Peptide

(TQAKRKKSLAMA, (Dostmann et al., 2000)) concentrations ranged from 125 nM to
saturating levels, and all assays were run in duplicate. Similar procedures were used to
determine the Ka values. Ten-microliter aliquots of peptide (200 µM) were added to each
assay, and the cGMP concentrations varied from 1 nM to saturating levels.

cGMP binding and dissociation
cGMP binding was assayed by incubating PKG enzyme (25 nM) for 90 minutes at 4°C
with various concentrations of [3H]-GMP, before precipitating and filtering as described
previously (Dostmann et al., 1996; Ruth et al., 1991). Similar procedures were used to
follow cGMP dissociation. Proteins were incubated at 4°C for 90 min in the presence of
250 nM [3H]-cGMP and dissociation was initiated by the addition of 10 µM cold cGMP.
Hill analysis was performed to determine Hill coefficients (nH) with the log[b/(bmax-b)]
plotted against the log of the cyclic nucleotide concentration [M], where b indicates
fractional cGMP binding. Skatchard analysis was used to determine single binding site
affinities by plotting [cGMP (bound/free)] against bound cGMP.

Electrospray ionization mass spectrometry (ESI)
Mass spectra of intact protein or cGMP-protein complexes were recorded on a time-offlight (TOF) mass spectrometer (Micromass LCT classic model, Waters, Manchester,
UK), fitted with a nano-electrospray source (Waters, Manchester, UK). Samples were
introduced by means of Au/Pd coated borosilicate capillaries (Cat. No. ES380, Proxeon
Biosystems, Odense, Denmark). Data were recorded in the positive ion mode between
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m/z 3000 - 8000 under conditions of increased pressure in the source and intermediate
pressure regions measured by built-in gauges in the mass spectrometer (Pirani gauge 7
mBar and Penning gauge 9 x 10-7 mBar) (Pinkse et al., 2004; Tahallah et al., 2001) and
processed using the MassLynx 4.0 software (Waters, Manchester, UK). Nanoflow
electrospray voltages were optimized for transmission of larger multimer protein
assemblies (capillary voltage 1800 -1900 V and cone voltage 120-140 V). For sample
preparation, PKG was buffer exchanged to a volatile buffer containing 200 mM
ammonium acetate (pH 6.7) with Ultrafree-0.4 centrifugal filter units (5000 NMWL,
Millipore, Bedford, MA, USA) and concentrated to 5 µM final. cGMP (20 µM final
concentration), when applied, was also dissolved in this buffer and preincubated with
PKG on ice for 5 min before analysis by ESI.
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Table 1: cGMP binding kinetics and stoichiometry of PKG mutants and wildtype

1

PKG

N1

KD2 [nM]

KD3 [nM]
Site A
Site B

nH4

WT

1.6 ± 0.2

40

6

110

1.5

G167E
E168G

0.8 ± 0.1
0.6 ± 0.05

382
195

-

327
197

0.6
0.8

G291E
E292G

0.8 ± 0.1
0.7 ± 0.1

26
18

29
21

-

0.9
0.9

R177K

1.5 ± 0.2

172

-

-

1.1

R301K
1.7 ± 0.2
12
1.1
2
3
3
N = Stoichiometry; : from [ H]-cGMP binding assays; : from Skatchard analysis;
4

Hill coefficient; the values represent the mean ± SEM of 6 to 9 experiments.

Table 2: Dissociation kinetics of PKG mutants and wildtype
PKG

k-1 [min-1]
Site A
Site B

τ1/2 [min]
Site A
Site B

WT

0.01 ± 0.005

5.5 ± 0.3

110

0.18

G167E

-

11.8 ± 0.1

-

0.09

E168G

-

22.2 ± 0.1

-

0.05

G291E
E292G

0.01 ± 0.003
0.01 ± 0.001

-

80
90

-

R177K
0.02 ± 0.003
6.7 ± 0.2.
55
0.15
R301K
0.07 ± 0.002
8.5 ± 0.2
15
0.12
The values represent the mean ± SEM of 6 to 9 experiments.
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Table 3: Catalytic activity of PKG mutants and wildtype
PKG

Activation
Ka [nM]

Substrate turn-over
1

-1

KM [nM]
705 ± 20

vmax [µmol x mg-1 x min-1]
10.5 ± 1.3

WT

53 ± 4

vmax [µmol x mg- x min ]
9.7 ± 0.2

G167E
E168G

-

1.6 ± 0.3
2.7 ± 0.1

150 ± 4
310 ± 5

2.9 ± 0.3
3.0 ± 0.3

G291E

18 ± 3

10.4 ± 0.2

654 ± 21

9.7 ± 1.0

E292G

37 ± 5

10.2 ± 0.4

968 ± 26

8.9 ± 0.3

R177K

620 ± 10

12.1 ± 0.1

653 ± 15

11.6 ± 0.2

R301K

16 ± 2
11.7 ± 0.5
890 ± 33
11.1 ± 0.5
The values represent the mean ± SEM of 6 to 9 experiments.
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Figure legends
Figure 1: (A) Sequence alignment of PKG I α and PKA I α cyclic nucleotide binding
sites; asterixes denote identical amino-acids, and residues targeted for site specific
mutagenesis for this study are indicated with arrows. (B) Domain composition of PKG I
α. (C) 10% SDS-PAGE of PKG I α wildtype (WT) and all affinity-purified mutants (1-5
µg protein per lane). (D) Stoichiometry of wild type and single-site cyclic nucleotide
binding mutants using [3H]-cGMP binding assays (see Methods).

Figure 2: Native electrospray ionization mass spectra of PKG wildtype (A, B) and
mutants E292G (C, D) and E168G (E, F) in the absence (left) and presence (right) of 20
µM cGMP. The mass spectra indicate distribution of charge state, the corresponding
insets show the respective de-convoluted mass spectra. Peaks marked with asterixes
indicate unidentified proteins.

Figure 3: Kinetic characterization of PKG mutants G167E (∆) and E168G ( ) in
comparison to PKG wildtype ( ). (A) [3H]-cGMP binding studies with (B) Skatchard and
(C) Hill analysis. (D, E) [3H]-cGMP dissociation from (D) slow and (E) fast cGMP
binding sites A and B, respectively. (F) cGMP dependent kinase activation of (G) PKG
site A mutants.

Figure 4: Kinetic characterization of PKG mutants G291E ( ) and E292G ( ) in
comparison to PKG wildtype ( ). (A) [3H]-cGMP binding studies with (B) Skatchard and
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(C) Hill analysis. (D, E) [3H]-cGMP dissociation from (D) slow and (E) fast cGMP
binding sites A and B, respectively. (F) cGMP dependent kinase activation of (G) PKG
site B mutants.

Figure 5: Substrate (LAMA, see Methods)-dependent kinase activity of PKG wildtype
( ), E168G ( ) and E292G ( ).

Figure 6: Kinetic characterization of PKG mutants R177K (x) and R301K ( )) in
comparison to PKG wildtype ( ). (A) cGMP dependent kinase activation (B) [3H]-cGMP
binding studies with (C) Hill analysis. (D) [3H]-cGMP dissociation from (D) slow and
fast sites A and B, respectively.

Figure 7: Model for activation of (A) site A knock-out mutants, (B) site B knock-out
mutants and (C) PKG wildtype.
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CHAPTER THREE: STRUCTURAL CHARACTERIZATION OF PKG USING
CRYSTALLOGRAPHY

Introduction
Within the family of cyclic nucleotide-dependent Ser/Thr protein kinases, PKG
shares the closest sequence homology and domain structure with PKA (Figures 1 A, 2 A).
In the past, X-ray crystallographic and NMR studies have proven invaluable to
characterize the structure of PKA. The crystal structure of the catalytic subunit of PKA
established for the first time the conserved structural features of the protein kinase
superfamily (Knighton et al., 1991). The catalytic subunit is a globular protein consisting
of two lobes - a highly dynamic small lobe that serves as an ATP binding site, and a large
lobe that serves as a framework for the catalytic machinery and also as a docking scaffold
for target proteins (substrates or inhibitors). The regulatory (R) subunit is highly dynamic
and functions primarily as a cAMP receptor (Figure 1 C) (Su et al., 1995). The parallel,
helical dimerization/docking (D/D) domain interacts with scaffold proteins, called Akinase anchoring proteins (AKAPs) (Kinderman et al., 2006; Newlon et al., 2001).
Following this domain is a variable and flexible linker region containing an inhibitor site
that docks to the active-site cleft of the catalytic (C) subunit and two in-tandem cAMPbinding domains (A and B). The phosphate-binding cassette (PBC), a helix-loop region
where cAMP binds, is the most conserved domain among all cyclic nucleotide binding
proteins, which include PKA/PKG, catabolite activator protein, hyperpolarizationactivated cyclic nucleotide-modulated channel, and exchange protein directly activated
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by cAMP. The crystal structure of the PKA holoenzyme (Figure 1 D), recently published
by Kim and colleagues (Kim et al., 2007; Kim et al., 2005), reveals in molecular detail
the highly dynamic processes and conformational changes that need to occur during PKA
activation.
In contrast, the mechanism of PKG activation is not very well described
structurally. Hydrodynamic and small-angle x-ray scattering techniques have confirmed
that cGMP binding induces significant conformational changes in the regulatory PKG
domain (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). The parallel,
alpha-helical interactions of the N-terminal domains (Schnell et al., 2005) have been
revealed using NMR and support an overall parallel orientation of the dimeric PKG
holoenzyme (Figures 2 A, B). The structure of other functional domains, such as the
cGMP binding sites and the catalytic domain, have not been characterized using
crystallography or NMR.
Large quantities of protein are generally a pre-requisite for crystallographic
screens. Since PKA can be easily expressed in bacteria, sufficient quantities can be
generated for crystallographic studies. Conversely, PKG can only be over-expressed in a
soluble form in a mammalian expression system (e.g. SF 9 insect cells), which generally
results in lower protein yields compared to a bacterial expression system. The goal of this
study was to develop a bacterial expression system for PKG deletion fragments in order
to yield sufficient quantities of protein for crystallographic studies and in order to
simplify the existing expression protocol. In addition, full-length PKG as well as deletion
fragments were tested for crystallization.
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Results
Crystallization of full-length PKG
First, highly concentrated PKG (5 mg/ml; Figure 3 A) was utilized to screen
various crystallization conditions (Hampton Screen # 1 and #2). Out of several hundred
conditions, four gave rise to crystals or crystal-like structures (Figures 3 B to E). Mixing
of full-length PKG with Hampton Screen #1, condition #24 (HS-1/24) (0.2 M Calcium
chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 20% v/v 2-Propanol) resulted
in 3-dimensional, bi-refringent crystals that were 50 x 30 x 20 µm in size (Figure 3 B).
The same type of crystals appeared when the enzyme storage buffer (without protein)
was mixed with buffer #24 (Figure 3 B, insertion). Therefore, these crystals were
comprised of salt, not protein. In Figure 3 C, full-length PKG was combined with HS1/17 (0.2 M Lithium sulfate monohydrate, 0.1 M Tris hydrochloride pH 8.5 and 30% w/v
Polyethylene glycol 4,000). After several days of incubation, granula and spherulites (5080 µm diameter) appeared. These micro-structures were indicative of protein-crystals,
since the control-drop with enzyme storage buffer produced a different form of salt
precipitation (Figure 3 C, insertion). Similarly, addition of PKG to HS-1/16 (0.1 M
HEPES sodium pH 7.5 and 1.5 M Lithium sulfate monohydrate) gave rise to a mixture of
protein precipitation and 30-50 µm crystals (Figure 3 D). These crystals most likely
consist of protein, because the control drop without protein produced a differently shaped
salt precipitation. When full-length PKG was combined and incubated with HS-1/13 (0.2
M Sodium citrate tribasic dihydrate, 0.1 M Tris hydrochloride pH 8.5, 30% v/v
Polyethylene glycol 400), 2-dimensional crystal-plates (50 x 30 µm in size (Figure 3E))
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grew after several days. These crystals were most promising, since the control drop was
lacking any (salt-) crystal formation (Figure 3 E, insertion). Therefore, the crystal-plates
in Figure 3 E can be attributed to PKG protein.

Deletion fragments of PKG are suitable for bacterial expression and form the basis
for crystallization
For X-ray crystallographic studies, vast amounts of protein are necessary to
screen numerous crystallization conditions. So far, the amount of PKG protein has been a
limiting factor for crystallization, since PKG can only be expressed in highly
sophisticated insect cell expression systems (e.g. SF 9). Since it is more challenging to
produce sufficient amounts of protein in SF9 cells, our goal was to establish a bacterial
expression system for PKG deletion fragments, focusing on the regulatory domain of
PKG. These PKG deletion mutants would then form the basis for crystallographic
studies.
We first focused on the cGMP-binding site B (Figure 4 A) and cloned three
different size constructs into the bacterial expression vector pET19b: construct B1 (E227G327), B2 (E227-Y336) and B3 (E227-K342). The different constructs were tested for
expression in E.coli BLR (Figure 4 B). Comparison to non-induced cells revealed that
constructs B1-B3 could be successfully over-expressed in bacteria with high yields
(approximately 5 mg per 50 ml E.coli).
After successfully establishing a bacterial expression system for a single cGMP
binding site, we attempted to clone both cGMP binding sites into the bacterial vector pET
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19b (Figure 5 A) and over-express it in bacteria. Two different size constructs have been
designed, RS3 (Q110-G327) and RS4 (Q110-K342), and both constructs were tested for
expression and solubility. As shown in Figure 5 B, RS3 and RS4 could both be overexpressed in E.coli BLR after induction with 0.4 mM IPTG. Comparing samples of
homogenate, supernatant and pellet of RS4 revealed that it is only partly expressed in a
soluble form in bacteria (Figure 5 C). About 30% of protein was detected in the pellet
and could not be recovered. Construct RS4 was over-expressed in bacteria and purified to
2.5 mg/ml final concentration. Next, RS4 was screened for crystallization using Hampton
Research Screens #1 and #2. Crystal-clusters were only seen for RS4 in combination with
0.2 M Calcium chloride dihydrate, 0.1 M Sodium acetate trihydrate pH 4.6 and 20% v/v
2-Propanol (Figure 5 D). To increase the likelihood of crystal formation in future studies,
crystallization screens should be repeated using higher protein concentrations. In
addition, the crystallization condition that resulted in RS4 crystals (Figure 5 D) should be
refined in varying pH, incubation temperature, salt- and precipitant concentrations.
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Discussion
Site-specific mutagenesis, hydrodynamic studies, as well as small angle x-ray
scattering approaches have been used extensively to gain insight into PKG folding
(Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al., 1997). In this study, we
attempted to address this question by crystallizing full-length PKG as well as PKGderived deletion fragments. As shown in Figures 3 B to E, we were able to obtain PKG
crystals and crystal-like structures. The crystallization conditions that produced PKG
crystals (Figure 3 E) or crystal-like structures (Figures 3 C, D) need to be refined in
future studies by varying pH, incubation temperature, salt- and precipitant concentrations.
Fine-tuning these conditions and utilizing macro- or micro- seeding may result in
enlarged PKG crystals that qualify for diffraction and ultimately reveal a structural model
for PKG. There are still some challenges associated with crystallizing full-length PKG,
such as protein availability through production in SF9 cells, as generation of welldiffracting crystals. Therefore, having smaller fragments of PKG serves multiple
purposes: smaller deletion fragments are more likely to be successfully expressed in
bacteria, and smaller proteins are also more likely to form crystals that are diffracting to
high resolution. In addition, removal of the N-terminal domain in the deletion fragments
prevents PKG-dimer formation as well as autophosphorylation events. The molecular
structure of the cGMP binding sites could elucidate very elegantly the mechanism of
cGMP binding and PKG activation. Furthermore, crystals of either full-length PKG or
smaller PKG fragments could be used for soaking in PKG-inhibitors such as DT2
(Dostmann et al., 2000; Taylor et al., 2004) and PKG-activators. This would not only
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extend our knowledge about the detailed molecular structure of PKG, but also answer
fundamental physiological questions about PKG activation and inhibition.
The static crystal structures will provide essential clues as to the conformational
versatility of PKG. However, complementary solution methods will be necessary to study
the dynamics of PKG in a more physiological environment. To meet this challenge, we
have used a variety of techniques, in addition to crystallography, to probe the structure
and function of PKG. We have used single point mutants to study cGMP binding and
kinase activation in vitro (Chapter 2), and non-FRET based indicators to monitor PKG
activity and cGMP signaling in living cells and in intact tissue (Chapters 4 and 5). Such
strategies are designed to unravel the complexity of PKG and cGMP signaling networks.
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Materials and Methods
Plasmid construction and bacterial expression
PKG deletion fragments were constructed by inserting different size constructs of
cGMP binding site B (B1: E227-G327; B2: E227-Y336; B3: E227-K342) or different
size constructs of the regulatory domain (RS3: Q110-G327; RS4: Q110-K342) of bovine
PKG I α into the bacterial expression vector pET19b (Novagen). All constructs were
inserted into the BamHI and EcoRI sites of pET19b, multiplied in E.coli DH5α, and
expressed in E.coli BLR (invitrogen). To test for bacterial expression, E.Coli BLR
transformed with PKG-containing pET19b vectors were cultured at 37°C for 12h after
protein

induction

with

0.4

mM

isopropyl-β-D-thiogalactoside

(IPTG).

After

centrifugation, PKG deletion fragment RS4 was purified using cyclic nucleotide affinity
chromatography as described previously (Feil et al., 1993). Purified PKG deletion
fragment RS4 (RS 4: 6 mg per 500 ml E.coli) was concentrated using Pall-Filtron
concentrators to 2.5 mg/ml final concentration and applied for crystallization screens.

Expression in SF9 cells
Full-length PKG was cloned into the pFAST-BAC mammalian expression vector
(invitrogen), over-expressed in SF 9 cells and purified using cyclic nucleotide affinity
chromatography as described previously (Feil et al., 1993). Purified protein (5 mg per
750 ml SF9-cells) was concentrated using Pall-Filtron concentrators to 5 mg/ml final
concentration and utilized for crystallization screens.
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Crystallization
Hampton Screens # 1 and #2 (Hampton Research, (Jancarik and Kim, 1991)) were
used to screen various crystallization conditions, mixing protein and buffer in a 1:1 ratio
and incubating at room temperature for several days using the hanging drop method. As
control, enzyme storage buffer was mixed with the crystallization buffer, in order to
distinguish between salt crystals and protein crystals.
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Figure Legends
Figure 1: Structural characterization of cAMP-dependent protein kinase (PKA). (A)
Schematic representation of PKA. (B) Catalytic subunit with small (white) and large lobe
(tan) bound to inhibitor peptide and ATP (red) (Taylor et al., 2005). The consensus site
peptide RRGAI docks to the active site cleft. (C) Model of the dimeric RIα subunits
showing the structured domains and the flexible linker (Taylor et al., 2005). The D/D
domain structure was solved by NMR and the cyclic nucleotide binding domains (CNB
(A) and (B)) were solved by crystallography. The flexibility of the linker was
demonstrated by fluorescence anisotropy where the red dots indicate sites where the
fluorescent probes are attached. (D) Crystal structure of a complex between the
regulatory (RIα) and catalytic subunits of PKA (Kim et al., 2005).

Figure 2: Domain structure of cGMP-dependent protein kinase (PKG). (A) Schematic
representation of PKG. (B) Structure of N-terminal dimerization sites (Schnell et al.,
2005).

Figure 3: Crystallization of full-length PKG. (A) 5-20 µg PKG were loaded on 10% SDSPAGE. Crystallization of PKG (5 mg/ml) using Hampton Research Screen condition 24
(B), condition 17 (C), condition 16 (D) and 13 (E). Insertions in the upper left depict a
mixture of enzyme storage buffer with the screened condition from Hampton Research.
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Figure 4: Bacterial expression of cGMP binding site B. (A) Schematic representation of
PKG highlighting cGMP binding site B (boxed area in green). (B) Comparison of noninduced (lane 2) and IPTG-induced E.coli BLR cells that were transformed with pET19bB1 (lane 3), pET19b-B2 (lane 4) or pET19b-B3 (lane 5).

Figure 5: Crystallization of PKG regulatory domain. (A) Schematic representation of
PKG highlighting the regulatory domain (boxed area in green). (B) Comparison of noninduced and IPTG-induced E.coli BLR cells that were transformed with empty pET19b
vector (lanes 2-3), pET19b-RS3 (lanes 4-5) or pET19b-RS4 (lanes 6-7). (C) Protein
expression of RS4 was tested for solubility by comparing samples from homogenate (lane
2), supernatant (lane 3) and pellet (lane 4). (D) Crystallization of RS4 (2.5 mg/ml) using
condition 24 of Hampton Screen.
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Abbreviations footnote: cGMP, cyclic-3',5'-guanosine monophosphate; [cGMP]i,
intracellular cGMP; cAMP, cyclic-3',5'-adenosine monophosphate; VSM, vascular
smooth muscle; PDE, phosphodiesterase; PKG, cGMP dependent protein kinase; pGC,
particular guanylyl cyclase; sGC, soluble guanylyl cyclase; NO, nitric oxide; ANP, atrial
natriuretic peptide; FRET, fluorescence resonance energy transfer; cpEGFP, circular
permutated EGFP; FlincG, fluorescent indicator of cGMP; DEA-NO, Diethylamine
NONOate; PROLI-NO, 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate
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Abstract
Here we report the design of unprecedented, non-FRET based cGMP-biosensors,
named FlincGs, to assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide
(ANP) induced synthesis of intracellular cGMP, [cGMP]i. Regulatory fragments of PKG
I α, PKG I β, and an N-terminal deletion mutant of PKG I α were fused to circular
permutated EGFP to generate α-, β-, and δ-FlincG, with high dynamic ranges and
apparent KD,cGMP values of 35 nM, 1.1 µM and 170 nM, respectively. All indicators
displayed significant selectivity for cGMP over cAMP, and 1.5 to 2.1 fold increases in
fluorescence intensity at 510 nm when excited at 480 nm. Surprisingly, FlincGs displayed
an additional excitation peak at 410 nm. δ-FlincG permitted ratiometric (480/410 nm)
measurements, with a cGMP specific 3.5 fold ratio change. In addition, δ-FlincG
presented cGMP association and dissociation kinetics sufficiently fast to monitor rapid
changes of [cGMP]i in intact cells. In unpassaged, adenoviral transfected vascular smooth
muscle (VSM) cells, δ-FlincG had an EC50,cGMP of 150 nM, and revealed transient global
cGMP elevations to sustained physiological NO (EC50,

DEA/NO

= 4 nM), and the decay

phase was dependent on the activity of PDE-5. In contrast, ANP elicited sustained submembrane elevations in [cGMP]i, which were converted to global cGMP elevations by
inhibition of PDE-5 by sildenafil. These results indicate that FlincG is an innovative tool
to elucidate the dynamics of a central biological signal –cGMP-, and that NO and
natriuretic peptides induce distinct cGMP patterning under the regulation of PDE-5, and
hence likely differentially engage cGMP targets.
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Introduction
Cyclic 3',5'-guanosine monophosphate (cGMP) has profound effects on cell
function through actions on cGMP-specific phosphodiesterases (PDEs) and cGMPdependent protein kinases (PKGs), as well as through several types of cyclic nucleotideactivated ion channels (CNGs) (Conti and Beavo, 2007; Francis et al., 2005; Hofmann,
2005; Hofmann et al., 2005). cGMP is synthesized by two distinct families of guanylyl
cyclases: i) the natriuretic peptide-specific, plasma membrane associated guanylyl
cyclases (pGC), and (ii) the nitric oxide (NO) activated, cytosolic soluble guanylyl
cyclases (sGC) (Cary et al., 2006; Garthwaite, 2005; Kuhn, 2005; Mullershausen et al.,
2005). Intracellular cGMP levels are terminated through the hydrolyzing activities of
cGMP-specific phosphodiesterases (Conti and Beavo, 2007).
In recent years, several FRET-based cGMP indicators have been developed in an
effort to monitor spatio-temporal dynamics of [cGMP]i (Honda et al., 2001; Nikolaev et
al., 2006; Russwurm et al., 2007). Particularly, Cygnet-type cGMP indicators have
significantly advanced our understanding of cGMP dynamics in VSM and other cell
types (Cawley et al., 2007; Honda et al., 2001; Honda et al., 2005; Honda et al., 2005;
Mongillo et al., 2006; Takimoto et al., 2005). However, FRET-based cGMP indicators
have limitations. They require a technically laborious dual emission detection system and
generally show overall low cyan/yellow emission ratio changes in intact cells.
Furthermore, at low, physiological NO-concentrations (< 10 nM), FRET-based cGMP
indicators are limited in their use to detect fluctuations in [cGMP]i (Cawley et al., 2007).
However, recent studies using purified cyclase, intact platelets and cerebellar cells have
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shown that sGC is activated at low-nanomolar NO concentrations (1 to 10 nM) (Mo et
al., 2004; Roy and Garthwaite, 2006). FRET-based cGMP indicators are also limited in
resolving possible compartmentalized intracellular cGMP signaling events using confocal
microscopy. It was recently suggested that in VSM cells and cardiac myocytes cGMP
signaling may be spatially segregated and that this functional compartmentalization may
be the cause of the unique actions of ANP and NO (Castro et al., 2006; Fischmeister et
al., 2006; Kass et al., 2007; Piggott et al., 2006; Takimoto et al., 2007). The goal of this
study was to develop previously undescribed, non-FRET biosensors suitable to monitor
the temporal changes of [cGMP]i in response to low-nanomolar NO or ANP, and to
investigate the spatial patterning of [cGMP]i, using real-time, confocal imaging
techniques.
The concept of non-FRET based biosensors, containing a single GFP-based
fluorescence unit was first described by Tsien and colleagues with the development of
Ca2+-sensitive ‘camgaroos’, by placing calmodulin at an insertion-permissive site within
the β sheets of GFP (Baird et al., 1999). Subsequently, circularly permutated EGFP
(cpEGFP) advanced non-FRET based biosensors even further and gave rise to the
development of ‘GCaMP’-type Ca2+ indicators, in which the Ca2+-dependent interaction
between calmodulin and its specific binding protein M13 was directly translated into
conformational changes and an increase in fluorescence intensity of the single fluorescent
molecule cpEGFP (Nakai et al., 2001; Tallini et al., 2006). We adopted this concept of
non-FRET biosensors to design cGMP indicators, called FlincGs (fluorescent indicators
of cGMP). FlincG indicators are composed of cpEGFP, N-terminally fused to regulatory
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domain fragments of PKG. The overall favorable kinetic and spectroscopic
characteristics of this single emission detection system permits for the first time the direct
examination of local cGMP dynamics in response to low-nanomolar NO or ANP in VSM
cells in real-time.
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Results and Discussion
Bioengineering FlincG biosensors from type I PKG.
FlincGs are composed of two in-tandem, PKG derived cGMP binding sites fused
to the N-terminus of cpEGFP (Figure 1 A). In contrast to GCaMP-type calcium indicators
(Nakai et al., 2001), FlincGs do not require intramolecular protein-protein interactions
between separate domains. Instead, dose-dependent binding of cGMP to both receptor
domains was sufficient to increase fluorescence intensity in cpEGFP (Figure 1 C, inset).
Previous studies using hydrodynamic and small-angle x-ray scattering techniques support
our findings that cGMP binding to the regulatory domain of PKG I induces substantial
conformational changes (Richie-Jannetta et al., 2006; Wall et al., 2003; Zhao et al.,
1997). α-FlincG was developed by attaching the entire regulatory domain of PKG I α
(residues 1-356) to cpEGFP (Figure 1 B). cGMP increased fluorescence intensity of this
construct by up to 1.5-fold, with an apparent KD of 35 nM (Figure 1 C) and with an
approximately 1,100 fold selectivity for cGMP over cAMP (Table 1).
To increase the dynamic range of [cGMP]i detection, we took advantage of the
fact that the activation constants of PKG I α and I β shift from 75 nM to approximately
1.0 to 1.8 µM (Ruth et al., 1991; Ruth et al., 1997; Wolfe et al., 1989). PKG I α and I β
are genetic splice-variants and consist of different N-termini, but are virtually identical
within their cGMP binding and catalytic domains (Ruth et al., 1991). Thus, we developed
β-FlincG, by connecting the regulatory domain of PKG I β to the N-terminus of cpEGFP
(Figure 1 B). As predicted, this FlincG variant demonstrated a shifted cGMP binding
constant of 1.1 µM (Figure 1 C, Table 1), indicating the significance of the N-terminus
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for modulating cGMP binding affinities. Interestingly, removal of the entire N-terminal
domain (∆1-77) of PKG I α resulted in δ-FlincG, which exhibited an apparent KD of 170
nM. This result is in accordance to an analogous PKG I α deletion fragment, ∆1-77/352670 for which a similar cGMP binding constant (KD = 218 nM) has been reported
(Dostmann et al., 1996). This finding further supports the concept that the N-terminal
domain of PKG, not the catalytic domain, primarily modulates cGMP binding affinities
of the FlincG indicators. Interestingly, the C-terminus of FlincGs did not affect
fluorescence intensity changes. Neither the linker sequence shown in Figure 1 B, which
was the product of a randomized cloning approach, nor attachment of the PKG catalytic
domain, or complete removal of any C-terminal appendage had any effect on overall
fluorescence intensity changes (data not shown).
Under cell-free conditions, α- and β-FlincG exhibited maximal 1.5 and 2.1-fold
intensity changes, respectively (Figure 1 C, Table 1). When expressed in VSM cells, the
maximal fluorescence increases of α- and β-FlincG were reduced to about 1.2-fold,
although these indicators retained high NO-sensitivity (EC50,

DEA-NO

= 0.3 and 12 nM,

respectively) (Table 2; Figure 1 D). Both biosensors contain their respective N-terminal
PKG dimerization sequences, which may give rise to interactions with endogenous PKG
and thus decreases their observed maximal intensity changes (Figure 1 D, Table 2). In
support of this idea, co-immunoprecipitation experiments demonstrated formation of
mixed dimers between wild-type PKG and α-, or β-FlincG (supp. Figure 1). However, δFlincG did not display any interaction with wildtype PKG, because it lacks the Nterminal dimerization domain (supp. Figure 1). Hence, we did not observe a reduction of

99

maximal fluorescence intensity when comparing purified δ-FlincG to indicator expressed
in intact VSM cells (Figures 1 C, E), whilst retaining high NO sensitivity (EC50, DEA-NO =
4 nM; Figure 1 E). This indicator was also highly selective for cGMP over cAMP (> 280
fold, Table 1).
Recently published FRET cGMP-sensors by Russwurm and colleagues (Russwurm et al.,
2007) display a comparable maximal FRET ratio change of 75 % for recombinant
protein. In living cells however, all FRET-indicators published so far, exhibit a
significant decrease in maximal FRET ratio change, ranging from 35 to 45 % (Cawley et
al., 2007; Honda et al., 2001; Nikolaev et al., 2006; Russwurm et al., 2007). In contrast,
FlincG cGMP biosensors have been designed to minimize interactions with endogenous
proteins and to maintain maximal fluorescence intensity changes in living cells while
retaining nanomolar NO sensitivity. Since δ-FlincG exhibits all these favorable
characteristics in living cells, we selected δ-FlincG as indicator suitable for studying
intracellular cGMP dynamics.

Kinetic, spectral analysis and environmental stability of δ-FlincG
A more refined spectral analysis revealed that in addition to the 491 excitation
maximum, δ-FlincG displayed a second, blue-shifted excitation peak at 410 nm (Figure 2
A). Furthermore, these excitation maxima at 410 and 491 nm respond differentially in
response to 1 µM cGMP. It should be noted, that all FlincG indicators possessed this
secondary 410 nm excitation maximum (data not shown), but only for δ-FlincG cGMP
decreased the emission intensity at 410 nm 0.5-fold, with a corresponding emission
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maximum at 507 nm (Figure 2 B). In addition, excitation at 480 nm yielded an emission
maximum at 511 nm (Figure 2 C) with an overall 1.75-fold fluorescence intensity
increase. Thus, our results are in contrast to the excitation emission spectra of EGFP and
previous cpEGFP based indicators, such as camgaroos and GCaMPs, which display only
one excitation maximum at 489 nm (Baird et al., 1999; Griesbeck et al., 2001; Nakai et
al., 2001).
Based on its dual excitation spectrum, δ-FlincG offers several technical
alternatives to previous FRET-based cGMP imaging techniques. First, the two excitation
wavelengths may be combined and analyzed ratiometrically (480/410 nm excitation),
similar to the Ca2+ indicator Fura (Grynkiewicz et al., 1985). As a result, the overall ratio
change increased up to 3.5 fold in vitro, and the overall apparent KD,cGMP was 488 nM,
with approximately 100-fold selectivity for cGMP over cAMP (Figure 2 D, Table 1).
Second, a single wavelength excitation system could be utilized by employing a 410/510
nm excitation/emission detection profile. However, for the initial experiments with δFlincG, the single wavelength approach (480/510 nm excitation/emission) was used,
because it is faster, has decreased risk of photo-bleaching, superior cGMP/cAMP
selectivity, and an advantageous apparent cGMP binding constant of 170 nM (Figure 1 C
and Table 1). Nonetheless, in future studies, the ratiometric approach (Figure 2 D) would
present a number of significant inherent advantages, including the determination of
[cGMP]i.
To examine further δ-FlincG’s utility as a [cGMP]i-biosensor, we investigated its
environmental stability under varying pH conditions (supp. Figure 2). Previously reported
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cpGFP based biosensors, such as camgaroos and GCaMPs, have displayed significant pH
sensitivity under physiological conditions with pKa values of 8.9 and 7.1, respectively
(Baird et al., 1999; Nakai et al., 2001). Elaborate mutational approaches have been
undertaken to reduce the environmental sensitivity of GFP and GFP-based variants. So
far, only Citrine, a yellow fluorescent protein (YFP) -based mutant, has been reported
with superior chloride and pH stability (pKa 5.7) compared to previous YFPs (Griesbeck
et al., 2001). In comparison, our results indicate that δ-FlincG did not require mutational
optimization to accomplish resistance to small changes in pH under physiological
conditions (pKa 6.1).
An important requirement for a biosensor is to have fast kinetics so that
intracellular temporal and spatial changes can be accurately monitored. Stopped-flow
experiments revealed a fast rate of cGMP association (kon = 5.9 x 106 s-1M-1; t1/2 = 0.12 s)
(Figure 3 A, Table 3). The dissociation constant determined by protein dilution was
equally rapid (koff = 4.2 s-1; t1/2 = 0.16 s) (Figure 3 B, Table 3). These rate constants
ensure that the rate limiting step for detecting [cGMP]i does not occur at the level of
cGMP association to or dissociation from the biosensor. Equally advantageous, δ-FlincG
should not act as a sink for [cGMP]i, because its cGMP binding constant (170 nM) is not
significantly different from its major endogenous receptors PKG I α and PDE 5 in
vascular smooth muscle (Ruth et al., 1991; Zoraghi et al., 2005). Superior spectral
characteristics, environmental stability and fast association/dissociation kinetics should
enable δ-FlincG to capture the rapid rise and fall of [cGMP]i in living VSM cells.
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Intracellular properties of δ-FlincG in vascular smooth muscle cells
Recently, we reported that primary, unpassaged VSM cells from rat aorta retain
the expression of key cGMP-signaling enzymes, such as PKG I, sGC and PDE5 (Cawley
et al., 2007). Transfection of VSM cells with δ-FlincG adenovirus resulted in an even
cytosolic distribution and nuclear exclusion of the indicator, with a 90% efficiency (inset,
Figure 4 A). To determine the apparent affinity of intracellular δ-FlincG for cGMP, VSM
cells were permeabilized with β-escin and the cells were exposed to different levels of
cGMP in Ca2+-free imaging buffer. Half-maximal fluorescence increases occurred at
150 nM cGMP (Figure 4A), similar to the value obtained for the purified biosensor (170
nM; Figure 1 C). With this approach, the level of intracellular cGMP can be estimated
from the fractional change in fluorescence.
An important criterion for intracellular cGMP sensors is that they exhibit
appropriately high sensitivity to NO, as previously reported for sGC (half-maximal NO:
1.7 nM for the purified enzyme, 11 nM for intact platelets,10 nM for cerebellar cells)
(Mo et al., 2004; Roy and Garthwaite, 2006). DEA-NO and PROLI-NO were used as
NO-donors due to their overall favorable fast chemistry of NO-release (see Methods).
DEA-NO (0.75 to 6.50 nM) induced concentration-dependent, transient increases in
[cGMP]i, corresponding to 10 nM to 1 µM (Figures 4 A, B). The corresponding half
activation constant (EC50,DEA-NO) was 4 nM (Figure 1 E; Table 2). Similarly, transient and
highly reproducible [cGMP]i changes were observed with 25 nM PROLI-NO (EC50, PROLINO

= 16 nM; Table 2; Figure 4 C). In contrast to NO-stimulated sGC, activation of the

plasma membrane associated guanylyl cyclase pGC-A using atrial natriuretic peptide
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(ANP) resulted in sustained levels of [cGMP]i (Figure 4 D), as demonstrated previously
in VSM cells using radio-immunoassays (Hamet et al., 1989; Leitman et al., 1988;
Winquist et al., 1984). These results promote δ-FlincG as exceptional biosensor for
physiological (low-nanomolar) NO- and ANP-induced cGMP dynamics in VSM cells.
NO-induced elevation of [cGMP]i requires activation of sGC. ODQ (10 µM), a
specific inhibitor of sGC activation (Brunner et al., 1995; Garthwaite et al., 1995;
Schrammel et al., 1996), prevented the PROLI-NO (50 nM) induced increase of cGMP
(Figure 4 E), indicating that the observed rise in [cGMP]i is indeed due to NO-induced
activation of sGC. The [cGMP]i also depends on its hydrolysis by PDE-5. Sildenafil, a
PDE-5 specific inhibitor (Corbin et al., 2003; Turko et al., 1999), greatly slowed the
decay in [cGMP]i in response to PROLI-NO (12 to 200 nM), supporting the concept of a
dynamic interplay between sGC production and PDE-5 mediated hydrolysis of cGMP
(Figure 4 F).

Spatial and temporal dynamics of NO- and ANP- induced cGMP signaling in δ-FlincG
transfected vascular smooth muscle cells
Our current understanding of the intracellular distribution of cGMP derives from
the fact that the predominant soluble guanylyl cyclase isoform sGC-α1β1 is largely
cytosolic, hence [cGMP]i should be cytosolic as well (Mullershausen et al., 2005). The
natriuretic peptides ANP, BNP and CNP, in contrast, specifically activate plasma
membrane associated guanylyl cyclases pGC-A and pGC-B and thus, may give rise to a
distinct spatial pattern of [cGMP]i (Fischmeister et al., 2006; Kass et al., 2007). However,
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the spatial distribution of [cGMP]i in response to NO and ANP has never been studied by
the means of high resolution confocal imaging techniques. FlincG-indicators should
permit the measurement of cGMP patterns in living cells.
A physiological dose of 1.5 nM NO induced a global, but transient, elevation in
[cGMP]i (Figures 5 A, B; supp. Movie 1), similar to measurements conducted with lower
resolution, epi-fluorescence microscopy (Figure 4 B, C). The membrane-permeant cGMP
analog (8-Br-cGMP, 50 µM) was applied to VSM cells and a uniform increase in
fluorescence was observed (supp. Movie 2), indicating homogenous expression of δFlincG in VSM cells. Forskolin (100 nM), which specifically activates the cAMP
signaling pathway, had no effect on fluorescence intensity (supp. Movie 3), consistent
with δ-FlincG selectivity for cGMP over cAMP.
In contrast to the transient NO-evoked [cGMP]i patterns, application of ANP (10 nM)
induced sustained synthesis of at least 1 µM [cGMP]i (Figures 5 C, D). This finding is in
agreement with our results shown in Figure 4 D, although different imaging techniques
(epi- versus confocal microscopy) give rise to variations in the onset of ANP response
(mean lag time: 25 ± 4 sec, Figure 5C; 45 ± 10 sec, Figure 4D). ANP induced local,
spatially segregated patterns of [cGMP]i at the plasma membrane of single VSM cells
(Figure 5 D; supp. Movie 4). To address spatial patterning due to uneven indicator
expression and cell movement, which may present potential problems in single
wavelength intensity measurements, we analyzed three-dimensional surface plots
(Supporting Figure 3) indicating uniform cellular distribution of δ-FlincG (from Figures

105

5 A and D). Supporting Figure 4 verifies that the cell morphology does not change over
time after NO or ANP application and that the cells do not move.
Spatially-confined cGMP signaling may be a combination of both local cGMP
synthesis and local degradation at the membrane. Recently, compartmentalized [cGMP]i
was reported in cardiac myocytes through specific activation of pGC by natriuretic
peptides (Castro et al., 2006; Mongillo et al., 2006; Takimoto et al., 2007). These studies
also suggested that cGMP specific PDEs maintain these local patterns of [cGMP]i elicited
through pGC. Our results indicate that ANP (10 nM) induced cGMP synthesis is
sustained and spatially confined in VSM cells (Figures 5 C, D). This spatial localization
in response to ANP was abolished, when VSM cells were preincubated with the PDE-5
inhibitor, sildenafil (Figure 5 E). Instead, a global increase in [cGMP]i was observed,
indicating that degradation of cGMP by PDE-5 prevents the cell’s interior from
experiencing an elevation of cGMP. These ANP-produced sub-membrane cGMP
elevations suggest local targeting of sub-membrane targets such as the calcium-sensitive
(BK) channel and SERCA-regulatory protein, phospholamban (Porter et al., 1998;
Robertson et al., 1993).
In conclusion, FlincG represents a previously undescribed generation of cGMP
biosensors that excels in monitoring [cGMP]i in response to physiological (lownanomolar) NO concentrations. FlincG should ultimately be suitable for development of
tissue-specific generation of transgenic mice with endogenous cGMP indicators, as has
been done recently for calcium sensing with GCaMP (Ji et al., 2004; Tallini et al., 2006).
The ratiometric possibilities of FlincG should enhance its versatility. FlincG revealed the
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differential role of PDE-5 in the modulation of global cGMP in response to NO donors,
and the spatial spread of cGMP away from the cell membrane in response to ANP.
FlincG holds the promise of unraveling the complex interplay between cGMP and
calcium signaling near the cell membrane.
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Materials and Methods
Fluorescence measurements in cultured vascular smooth muscle cells (P0)
VSM cells were harvested from rat aortic tissue and cultured as described previously
(Cawley et al., 2007). For transfection, 100 µl of adenovirus (107 to 109 per ml titer) were
applied to 50% confluent VSM cells (P0) and incubated 24 to 48h at 37°C, 5% CO2 until
a 90 % transfection efficiency in VSM cells was achieved. Epi-fluorescence imaging was
performed by incubating cells in imaging buffer (10mM TES (pH 7.4), 1 g/L D-glucose,
Hank’s Balanced Salt Solution (HBSS, Mediatech, Inc., Herndon, VA) at 37°C using a
Delta T4 open culture system (Bioptechs, Butler, PA). A Nikon Diaphot 200 microscope
outfitted with a Nikon 40x/1.30 oil objective, a cooled charge-coupled device camera
(ORCA ER; Hamamatsu, Japan), and a mercury-halide lamp, X-CITE 120 (EXFO
Photonics, Toronto, ON), were used to image individual cells with 3 seconds
acquisitions. Imaging of FlincG indicators was controlled by Metafluor 6.2 software
(Universal Imaging, Media, PA) using a D480/20m excitation filter, 505drxr dichroic
mirror and D535/30m emission. For confocal imaging, P0 VSM cells were imaged using
a spinning disk confocal system (Andor) outfitted on a Nikon E600SN microscope with a
60x water dipping objective (NA 1.0), and iXon ENCCD DVB camera with 5 frames/sec
acquisition speed and 64 msec exposure time exciting with a solid state laser at 488 nm,
and collecting the emission at 510 nm. Data analysis was performed with custom written
software developed by Dr. Adrian Bonev. For confocal microscopy, cGMP responses
were investigated upon local application (5 to 50 µl) and subsequent diffusion of
DEA/NONOate (Calbiochem), PROLI/NONOate (Cayman Chemicals), ANP (Sigma),
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Sildenafil (Pfizer), ODQ (Sigma), 8-Br-cGMP (BioLog) and Forskolin (Sigma).
Approximately 75% of the data collected were rejected due to cell movement and
morphology changes during the course of the experiments. For epi-fluorescence
microscopy, chemicals were distributed evenly by mixing with imaging buffer.
Calibration of adenoviral transfected VSM cells was performed in Hepes-buffered, Ca2+free PSS pH 7.4. VSM cells were permeabilized with 20 µM β-escin, exposed to
increasing cGMP concentrations (0 to 2 µM) and analyzed using the epi-fluorescence
microscope facility. For NO-titration, δ-FlincG transfected VSM cells were exposed to
0.4 nM - 500 nM DEA-NO (t1/2 = 2.4 min at 37°C, pH 7.4), or to 1.5 nM - 2 µM PROLINO (t1/2 = 1.8 sec at 37°C, pH 7.4). Data were analyzed using the Metafluor software and
dose-response curves were calculated with GraphPadPrism.
Further methods are provided in supporting information 1.
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Table 1: cGMP and cAMP selectivity of recombinant FlincG biosensors
FlincG isoform

(F/F0)max

KD,cGMP [µM]

KD,cAMP [µM]

cGMP/cAMP

Alpha1

1.55 ± 0.05 [4]

0.035 ± 0.010 [4]

40 ± 8 [3]

1140

Beta1

2.05 ± 0.03 [5]

1.100 ± 0.050 [5]

31 ± 10 [4]

30

Delta1

1.75 ± 0.03 [5]

0.170 ± 0.020 [5]

48 ± 10 [4]

280

Delta2

3.50 ± 0.06 [4]

0.488 ± 0.004 [4]

48 ± 10 [4]

100

1

: single excitation at 480 nm, emission at 510 nm (Fig. 1C); 2: ratiometric excitation at 410 and 480
nm, emission at 510 nm (Fig. 2D); the values represent the mean ± SEM of n Numbers of
experiments (shown in brackets);0

Table 2: NO-titration and Calibration of FlincG biosensors in VSM cells
FlincG isoform

EC50, DEA-NO [nM]

EC50, PROLI-NO [nM]

(F/F0)max

EC150, cGMP [nM]

Alpha

0.3 ± 0.2 [6]

─

1.12 ± 0.08

─

Beta

12 ± 0.4 [6]

─

1.19 ± 0.06

─

Delta

4 ± 0.5 [8]

16 ± 2 [6]

1.75 ± 0.03

150 ± 12 [4]

: calibration for cGMP in β-escin permeabilized VSM cells; the values represent the mean ± SEM of n
Numbers of experiments (shown in brackets);

1

Table 3: cGMP association and dissociation kinetics
FlincG isoform

kon [s-1M-1]

t1/21 [s]

koff [s-1]

t1/22 [s]

Delta

5.9 x 106 [4]

0.12 [4]

4.2 [3]

0.16 [3]

1

: t1/2 cGMP association; 2: t1/2 cGMP dissociation; the values represent the mean
± SEM of n Numbers of experiments (shown in brackets);
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Figure legends:
Figure 1: Characterization of FlincG biosensors as recombinant proteins and in VSM
cells. (A) Schematic architecture: fusion of regulatory fragments of PKG I to cpEGFP
induces cGMP dependent changes in fluorescence emission intensity. (B) Domain
structure: α-, β- and δ-FlincG utilize regulatory fragments of PKG I α and PKG I β. (C)
cGMP dose response curves for α-, β- and δ-FlincG (Table 1); inset: cGMP dosedependent increase in fluorescence intensity shown for α-FlincG. NO-titration of (D) αand β-FlincG and (E) δ-FlincG in single VSM cells using epi-fluorescence microscopy
(see Table 2).

Figure 2: Spectral analysis of δ-FlincG. (A) Excitation spectrum of δ-FlincG in presence
and absence of 1 µM cGMP detected at 510 nm. Emission spectra excited at (B) 410 and
(C) 480 nm in the presence and absence of 1 µM cGMP. (D) Ratiometric (480/410 nm)
dose response curves for cGMP and cAMP detected at 510 nm.

Figure 3: cGMP binding kinetics of δ-FlincG. (A) cGMP association kinetics using
stopped-flow fluorometry. Slopes represent the initial association velocities at different
cGMP concentrations (inset). (B) cGMP dissociation kinetics using a dilution protocol
(see Methods). Intensity changes were detected using a fluo-spectrophotometer.

Figure 4: Temporal dynamics of cGMP in VSM cells. (A) Calibration of δ-FlincG.
Adenovirus-transfected VSM cells (inset) were permeabilized with β-escin and exposed
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to increasing cGMP concentrations (25 nM - 2 µM). (B, C) Temporal cGMP dynamics in
VSM cells were analyzed upon addition of 0.75 - 6.5 nM DEA-NO (B), 25 nM PROLINO (C) and 50 nM ANP (D) using epi-fluorescence microscopy . (E, F) Effects of ODQ
and Sildenafil on δ-FlincG-transfected VSM cells. Cells were exposed repeatedly to 50
nM PROLI-NO in presence and absence of 10 µM ODQ (E) and to 12 to 200 nM PROLINO in presence of 50 µM Sildenafil (F). For each experimental series, n numbers are 4 to
10.

Figure 5: Spatial analysis of the NO and ANP pools of cGMP in δ-FlincG transfected
VSM cells. [cGMP]i in response to (A, B) 1.5 nM DEA-NO and (C, D) 10 nM ANP
using confocal microscopy. Regions of interest and their corresponding intensity traces
are indicated with arrows and corresponding color boxes. Acquisition speed = 5
frames/sec; exposure time = 64 msec. (E) Application of 10 nM ANP after preincubation
with 100 µM Sildenafil. For each experimental series, n numbers are 4 to 6.
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Figure 1:
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Figure 2:
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Figure 3:
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Figure 4:
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Figure 5:
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Supporting Information 1:
Materials and Methods
Plasmid construction and bacterial expression
FlincG variants were constructed by fusing the regulatory domains of bovine PKG I α (1356, α-FlincG), PKG I β (1-372, β-FlincG), or a deletion mutant of PKG I α (77-356, δFlincG) to the 5’ end of circular permutated EGFP (cpEGFP 149-144, (Nakai et al.,
2001)) by overlapping PCR. For bacterial expression, PKG regulatory domains were
preceded by an XhoI site, and a start codon (ATG). cpEGFP 149-144 was connected at
the 3’ end to a 17 aminoacid sequence (LSDFNIIDTLGVGGFGR) by overlapping PCR
and was followed by a stop codon and an EcoRI site. The entire FlincG coding sequence
was inserted into the XhoI and EcoRI sites of pRSET-A, multiplied in E.coli DH5α and
expressed in E.coli BLR. Similarly, mammalian adenoviral FlincG constructs were
preceded at the 5’end by a BamHI site and a Kozak sequence (ACCATGG), inserted into
the BamHI and EcoRI sites of pENTR vector and sub-cloned into pAd-DEST (ViraPower
adenoviral expression system, invitrogen). For in vitro studies, E.Coli BLR transformed
with FlincG-containing pRSET-A vectors were cultured at 25°C for 12h after protein
induction with 0.4 mM isopropyl-β-D-thiogalactoside (IPTG). After centrifugation,
FlincG variants were purified using cyclic nucleotide affinity chromatography as
described previously (Dostmann et al., 2000; Feil et al., 1993).
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In vitro characterization
Excitation spectra (detected at 510 nm) and emission spectra (excited at 410 or 480 nm)
were taken using a fluorescence spectrophotometer F4500 (Hitachi, Tokyo, Japan). 200
nM purified FlincG was combined with increasing concentrations of cGMP (0-10 µM) or
cAMP (0-100 µM) to generate cNMP dose response curves. For pH titration experiments
at 200 nM protein concentration, phosphate buffer (for pH 6.5) was replaced with either
citrate (for pH 5 to 6), Hepes-buffered HBSS (for pH 7 to 8), or with glycine (for pH 8.5
to 9). The pH-titration was calculated for each pH point by monitoring the baseline (F0)
in absence of cGMP, and by determining the increase in fluorescence (F) in presence of 1
µM cGMP. This approach represents the difference between zero-cGMP and saturating
cGMP depending on various pH conditions. Kinetic measurements for cGMP association
were

performed

utilizing

a

stopped-flow

instrument

(BioLogic

Science

Instruments µSFM-20, France). Typically, four independent mixing experiments (10 µM
protein, 0 to 2 µM cGMP) were averaged before mono-exponential fitting with a Simplex
routine in Bio-Kine (v. 3.0) proprietary software provided by BioLogic. cGMP
dissociation kinetics were determined by mixing 500 nM FlincG protein and 150 nM
cGMP, followed by subsequent > 5 fold dilution in Hepes-buffered HBSS pH 7.4 to final
cGMP concentrations below 30 nM. The intensity changes indicative of cGMP
dissociation were recorded using the fluorescent spectrophotometer F4500 (Hitachi,
Tokyo, Japan). For immunoprecipitation studies, a mixture of 5 µg FlincG protein in
PSS, 0.1 % NP-40 and 5 µg protein of the corresponding PKG isoform was combined
with 2 µg rabbit anti-GFP antibody (Invitrogen, Molprobes) and incubated at 25°C for 30
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minutes. The protein-protein complex was precipitated with Protein A/G beads and was
washed > 3 times with PBS, 0.1% NP-40 buffer. Beads were resuspended in Laemmli
buffer and subjected to 10 % SDS-PAGE.
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Supporting Figure legends
Supporting Figure 1: 10 % SDS-PAGE showing the co-immunoprecipitation of FlincG
variants with their corresponding PKG isoforms using a rabbit anti-GFP antibody.

Supporting Figure 2: pH titration of normalized fluorescence. For each pH point, the
baseline (F0) was monitored in absence of cGMP, and the increase in fluorescence (F)
was determined in presence of 1 µM cGMP.

Supporting Figure 3:
Uniform distribution of fluorescence intensity of δ-FlincG in VSM cells. (A, C) Images
showing the distribution of fluorescence intensity in VSM cells represented in Figures 5
A (NO) and D (ANP) at time points zero. (B, D) Three-dimensional surface plots. X- and
Y-axes represent the orientation of the cells and the Z-axis shows the fluorescence
intensities.

Supporting Figure 4:
Cell morphology of δ-FlincG transfected VSM cells. (A, B) Fluorescence images of
VSM cells depicted in Figures 5 A and D. Dotted lines trace the cell shape over the timecourse of the experiment. Arrows indicate the regions of interest in Figure 5. The insets
in (B) magnify the region of interest and verify the absence of cellular movement and
morphology changes over time.
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Supporting Movie 1: Application of 1.5 nM DEA-NO to δ-FlincG transfected VSM cell
Supporting movie 2: Application of 50 µM 8-Br-cGMP to δ-FlincG transfected VSM cell
Supporting movie 3: Application of 100 nM Forskolin to δ-FlincG transfected VSM cell.
Supporting movie 4: Application of 10 nM ANP to δ-FlincG transfected VSM cells;
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Supporting Figure 1:
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Supporting Figure 2:
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Supporting Figure 3:
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Supporting Figure 4:

126

References
Baird GS, Zacharias DA and Tsien RY. Circular permutation and receptor insertion
within green fluorescent proteins. Proc Natl Acad Sci U S A 96(20): 11241-6, 1999.
Brunner F, Stessel H and Kukovetz WR. Novel guanylyl cyclase inhibitor, ODQ
reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Lett
376(3): 262-6, 1995.
Cary SP, Winger JA, Derbyshire ER and Marletta MA. Nitric oxide signaling: no
longer simply on or off. Trends Biochem Sci 31(4): 231-9, 2006.
Castro LR, Verde I, Cooper DM and Fischmeister R. Cyclic guanosine
monophosphate compartmentation in rat cardiac myocytes. Circulation 113(18): 2221-8,
2006.
Cawley SM, Sawyer CL, Brunelle KF, van der Vliet A and Dostmann WR. Nitric
oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell
Signal 19(5): 1023-33, 2007.
Conti M and Beavo J. Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev
Biochem 76: 481-511, 2007.
Corbin JD, Blount MA, Weeks JL, 2nd, Beasley A, Kuhn KP, Ho YS, Saidi LF,
Hurley JH, Kotera J and Francis SH. [3H]sildenafil binding to phosphodiesterase-5 is
specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63(6):
1364-72, 2003.
Dostmann WR, Koep N and Endres R. The catalytic domain of the cGMP-dependent
protein kinase Ialpha modulates the cGMP-binding characteristics of its regulatory
domain. FEBS Lett 398(2-3): 206-10, 1996.
Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R and Tegge WJ. Highly
specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha
inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A 97(26): 14772-7, 2000.
Feil R, Muller S and Hofmann F. High-level expression of functional cGMP-dependent
protein kinase using the baculovirus system. FEBS Lett 336(1): 163-7, 1993.
Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J and
Vandecasteele G. Compartmentation of cyclic nucleotide signaling in the heart: the role
of cyclic nucleotide phosphodiesterases. Circ Res 99(8): 816-28, 2006.

127

Francis SH, Blount MA, Zoraghi R and Corbin JD. Molecular properties of
mammalian proteins that interact with cGMP: protein kinases, cation channels,
phosphodiesterases, and multi-drug anion transporters. Front Biosci 10: 2097-117, 2005.
Garthwaite J. Dynamics of cellular NO-cGMP signaling. Front Biosci 10: 1868-80,
2005.
Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K and Mayer B. Potent
and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48(2): 184-8, 1995.
Griesbeck O, Baird GS, Campbell RE, Zacharias DA and Tsien RY. Reducing the
environmental sensitivity of yellow fluorescent protein. Mechanism and applications. J
Biol Chem 276(31): 29188-94, 2001.
Grynkiewicz G, Poenie M and Tsien RY. A new generation of Ca2+ indicators with
greatly improved fluorescence properties. J Biol Chem 260(6): 3440-50, 1985.
Hamet P, Pang SC and Tremblay J. Atrial natriuretic factor-induced egression of
cyclic guanosine 3':5'-monophosphate in cultured vascular smooth muscle and
endothelial cells. J Biol Chem 264(21): 12364-9, 1989.
Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280(1):
1-4, 2005.
Hofmann F, Biel M and Kaupp UB. International Union of Pharmacology. LI.
Nomenclature and structure-function relationships of cyclic nucleotide-regulated
channels. Pharmacol Rev 57(4): 455-62, 2005.
Honda A, Adams SR, Sawyer CL, Lev-Ram V, Tsien RY and Dostmann WR.
Spatiotemporal dynamics of guanosine 3',5'-cyclic monophosphate revealed by a
genetically encoded, fluorescent indicator. Proc Natl Acad Sci U S A 98(5): 2437-42,
2001.
Honda A, Moosmeier MA and Dostmann WR. Membrane-permeable cygnets: rapid
cellular internalization of fluorescent cGMP-indicators. Front Biosci 10: 1290-301, 2005.
Honda A, Sawyer CL, Cawley SM and Dostmann WR. Cygnets: in vivo
characterization of novel cGMP indicators and in vivo imaging of intracellular cGMP.
Methods Mol Biol 307: 27-43, 2005.
Ji G, Feldman ME, Deng KY, Greene KS, Wilson J, Lee JC, Johnston RC, Rishniw
M, Tallini Y, Zhang J, Wier WG, Blaustein MP, Xin HB, Nakai J and Kotlikoff MI.

128

Ca2+-sensing transgenic mice: postsynaptic signaling in smooth muscle. J Biol Chem
279(20): 21461-8, 2004.
Kass DA, Takimoto E, Nagayama T and Champion HC. Phosphodiesterase regulation
of nitric oxide signaling. Cardiovasc Res 75(2): 303-14, 2007.
Kuhn M. Cardiac and intestinal natriuretic peptides: insights from genetically modified
mice. Peptides 26(6): 1078-85, 2005.
Leitman DC, Andresen JW, Catalano RM, Waldman SA, Tuan JJ and Murad F.
Atrial natriuretic peptide binding, cross-linking, and stimulation of cyclic GMP
accumulation and particulate guanylate cyclase activity in cultured cells. J Biol Chem
263(8): 3720-8, 1988.
Mo E, Amin H, Bianco IH and Garthwaite J. Kinetics of a cellular nitric
oxide/cGMP/phosphodiesterase-5 pathway. J Biol Chem 279(25): 26149-58, 2004.
Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR,
Pozzan T, Kass DA, Paolocci N, Houslay MD and Zaccolo M. Compartmentalized
phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMPdependent pathway. Circ Res 98(2): 226-34, 2006.
Mullershausen F, Koesling D and Friebe A. NO-sensitive guanylyl cyclase and NOinduced feedback inhibition in cGMP signaling. Front Biosci 10: 1269-78, 2005.
Nakai J, Ohkura M and Imoto K. A high signal-to-noise Ca(2+) probe composed of a
single green fluorescent protein. Nat Biotechnol 19(2): 137-41, 2001.
Nikolaev VO, Gambaryan S and Lohse MJ. Fluorescent sensors for rapid monitoring
of intracellular cGMP. Nat Methods 3(1): 23-5, 2006.
Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M and Rich TC.
Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular
compartments. J Gen Physiol 128(1): 3-14, 2006.
Porter VA, Bonev AD, Knot HJ, Heppner TJ, Stevenson AS, Kleppisch T, Lederer
WJ and Nelson MT. Frequency modulation of Ca2+ sparks is involved in regulation of
arterial diameter by cyclic nucleotides. Am J Physiol 274(5 Pt 1): C1346-55, 1998.
Richie-Jannetta R, Busch JL, Higgins KA, Corbin JD and Francis SH. Isolated
regulatory domains of cGMP-dependent protein kinase Ialpha and Ibeta retain
dimerization and native cGMP-binding properties and undergo isoform-specific
conformational changes. J Biol Chem 281(11): 6977-84, 2006.

129

Robertson BE, Schubert R, Hescheler J and Nelson MT. cGMP-dependent protein
kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J
Physiol 265(1 Pt 1): C299-303, 1993.
Roy B and Garthwaite J. Nitric oxide activation of guanylyl cyclase in cells revisited.
Proc Natl Acad Sci U S A 103(32): 12185-90, 2006.
Russwurm M, Mullershausen F, Friebe A, Jager R, Russwurm C and Koesling D.
Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a
systematic approach. Biochem J 407(1): 69-77, 2007.
Ruth P, Landgraf W, Keilbach A, May B, Egleme C and Hofmann F. The activation
of expressed cGMP-dependent protein kinase isozymes I alpha and I beta is determined
by the different amino-termini. Eur J Biochem 202(3): 1339-44, 1991.
Ruth P, Pfeifer A, Kamm S, Klatt P, Dostmann WR and Hofmann F. Identification
of the amino acid sequences responsible for high affinity activation of cGMP kinase
Ialpha. J Biol Chem 272(16): 10522-8, 1997.
Schrammel A, Behrends S, Schmidt K, Koesling D and Mayer B. Characterization of
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxidesensitive guanylyl cyclase. Mol Pharmacol 50(1): 1-5, 1996.
Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL,
Champion HC and Kass DA. Compartmentalization of cardiac beta-adrenergic inotropy
modulation by phosphodiesterase type 5. Circulation 115(16): 2159-67, 2007.
Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose
DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ and Kass DA. cGMP
catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3dependent mechanism. Circ Res 96(1): 100-9, 2005.
Tallini YN, Ohkura M, Choi BR, Ji G, Imoto K, Doran R, Lee J, Plan P, Wilson J,
Xin HB, Sanbe A, Gulick J, Mathai J, Robbins J, Salama G, Nakai J and Kotlikoff
MI. Imaging cellular signals in the heart in vivo: Cardiac expression of the high-signal
Ca2+ indicator GCaMP2. Proc Natl Acad Sci U S A 103(12): 4753-8, 2006.
Turko IV, Ballard SA, Francis SH and Corbin JD. Inhibition of cyclic GMP-binding
cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Mol Pharmacol 56(1): 124-30, 1999.
Wall ME, Francis SH, Corbin JD, Grimes K, Richie-Jannetta R, Kotera J,
Macdonald BA, Gibson RR and Trewhella J. Mechanisms associated with cGMP

130

binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci U S A
100(5): 2380-5, 2003.
Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F and Rapoport RM.
Atrial natriuretic factor elicits an endothelium-independent relaxation and activates
particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci U S A
81(23): 7661-4, 1984.
Wolfe L, Corbin JD and Francis SH. Characterization of a novel isozyme of cGMPdependent protein kinase from bovine aorta. J Biol Chem 264(13): 7734-41, 1989.
Zhao J, Trewhella J, Corbin J, Francis S, Mitchell R, Brushia R and Walsh D.
Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent
protein kinase studied by small angle X-ray scattering in solution. J Biol Chem 272(50):
31929-36, 1997.
Zoraghi R, Bessay EP, Corbin JD and Francis SH. Structural and functional features
in human PDE5A1 regulatory domain that provide for allosteric cGMP binding,
dimerization, and regulation. J Biol Chem 280(12): 12051-63, 2005.

131

CHAPTER FIVE: NON-GENETIC DELIVERY SYSTEM FOR NOVEL cGMPBIOSENSORS INTO INTACT ARTERIES REVEALS cGMP DYNAMICS IN
RESPONSE TO NITRIC OXIDE AND ATRIAL NATRIURETIC PEPTIDE.

Introduction
Nitric oxide (NO) and atrial natriuretic peptide (ANP) were first suggested to
regulate vascular smooth muscle tone more than 25 years ago. In 1980, Furchgott &
Zawadzki (Furchgott and Zawadzki, 1980) first described endothelium-dependent
relaxation, a phenomenon whereby acetylcholine relaxes isolated preparations of blood
vessels only if the vascular endothelium lining the vessels is present and intact.
Subsequent studies revealed that acetylcholine and other agents (including bradykinin,
histamine and 5-hydroxytryptamine) release a transferable factor (endothelium-derived
relaxing factor, EDRF) which is unstable, acts via stimulation of the soluble guanylate
cyclase and is inhibited by hemoglobin and methylene blue (Furchgott et al., 1984).
Several years later, Furchgott as well as Ignarro proposed that EDRF might be nitric
oxide (Furchgott, 1988; Ignarro et al., 1988). Since then, the vasodilatory effect of NO
has been studied in great detail, and it is now known that it is caused by a soluble
guanylyl cyclase-mediated increase in [cGMP]i (Mullershausen et al., 2005). Another
regulatory factor for vascular smooth muscle tone was discovered in 1981, when Adolfo
de Bold isolated a potent diuretic and natriuretic factor from rat atrial extracts (de Bold et
al., 1981). Atrial natriuretic peptide (ANP) has been shown to bind to the membranebound, particulate gunalylyl cyclase A (GC-A), thereby increasing [cGMP]i (Garbers,
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1991; Garbers and Lowe, 1994). Although several methods exist to detect cGMP in vitro,
such as biosensors (Honda et al., 2001; Nikolaev et al., 2006; Russwurm et al., 2007),
radio-immunoassays (Brooker et al., 1979), patch clamping (Castro et al., 2006) and
patch cramming (Trivedi and Kramer, 1998), it has been challenging to follow [cGMP]i
dynamics in intact tissue under near-physiological conditions. Commonly used myograph
studies are suitable to monitor changes in vessel diameter in response to various stimuli,
thereby indirectly predicting fluctuations in cGMP and calcium dynamics. However,
there is growing demand for methods to directly detect [cGMP]i in intact arteries.
Recently, FRET-based cGMP biosensors (Cygnets) were permanently fused to membrane
permeable peptides (MPP) and shown to be fully functional in cultured VSM cells and in
intact vessels (Honda et al., 2005). However, these FRET-based indicators have limited
utility in studying spatio-temporal cGMP dynamics in intact tissue, since they display
overall low FRET-ratio change in cells, low responsiveness to physiological NO and
ANP concentrations, and have limited use for high-speed, real-time confocal microscopy.
These restrictions prompted us to develop a non-genetic delivery system for our novel,
non-FRET cGMP biosensors, FlincGs (Chapter 4), utilizing intact arteries as a model
system. Here, we report for the first time a non-FRET based cGMP biosensor suitable to
detect NO- and ANP-dependent [cGMP]i responses in cerebral arteries.
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Results and discussion
Previously, several genetic methods, as well as viral delivery systems, have been
reported to translocate small nucleotides or plasmids into intact tissue (Bolz and Pohl,
2003; Earley et al., 2005; Tang et al., 2003; Yao and Wang, 1995; Zhang et al., 2005).
Since all these methods have limited use to translocate large-size plasmids into intact
tissue and require long incubation times (several days) for successful delivery, we have
used a different approach in this study. Npys-TAT, a 2,2’-(5-nitropyridine (Npys))
activated form of the membrane-permeable TAT-peptide (Rabanal, 2003), was mixed
with purified α-FlincG protein in vitro and the activated TAT peptide bound reversibly to
surface cysteines of α-FlincG (Figure 1 A). TAT-labeling of α-FlincG preserved overall
cGMP (Ka = 40 ± 3 nM) over cAMP (Ka = 54 ± 8 µM) selectivity and maximal 1.35-fold
fluorescence intensity change of the cGMP biosensor, indicating that the chemical
labeling process does not interfere with critical FlincG folding to allow detection of
[cGMP]i (Figure 1 B; see also Table 1 in chapter 4). This stable TAT-SS-FlincG complex
translocated randomly and distributed uniformly into all cell types found in small
resistance vessels, including VSM cells (Figures 2 A, B). Upon intracellular entry, the
reducing environment cleaves the TAT peptide and releases α-FlincG. To verify
cytosolic localization of α-FlincG, we applied 8-Br-cGMP (50 µM) to FlincG-labeled,
cerebral arteries (Figure 2 C).
Recent studies in cultured VSM cells utilizing FlincG indicators revealed distinct
spatio-temporal [cGMP]i kinetics depending on NO or ANP stimuli (Chapter 4, Figures 4
and 5). Interestingly, similar temporal cGMP dynamics were detected in intact cerebral
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arteries utilizing α-FlincG. Application of NO induced transient cGMP responses (lag
time = 25 sec) with a maximum 1.3 fold increase in fluorescence intensity (Figure 3 A).
The spatial distribution of [cGMP]i in response to NO in cerebral arteries could not be
determined due to the slow frame rate of the confocal imaging system utilized in these
experiments. In contrast to NO-evoked, transient cGMP kinetics, application of ANP
(100 nM) induced sustained cGMP synthesis (lag time = 40 sec) with maximum 1.3 fold
increase in fluorescence intensity (Figure 3 B). The spatial distribution of ANP-evoked
[cGMP]i could not be resolved because of low-resolution epi-fluorescence imaging
techniques. The overall low increase in intensity for α-FlincG is consistent with previous
observations showing that different FlincG indicators (α- and β- FlincGs) generate small
changes in the maximal fold intensity increase in cells due to interactions with
endogenous proteins (Chapter 4: Figure 1 D; Tables 1 and 2).
Although this novel, non-genetic delivery method for FlincG biosensors holds the
potential to advance our understanding of the spatio-temporal dynamics of [cGMP]i in
intact arteries, several complications still remain: relatively long incubation times (1215h) of the arteries are required to successfully deliver TAT-FlincG into VSM cells. This
may result in precipitation of TAT-FlincG protein, as well as downregulation of key
enzymes of the cGMP signaling cascade over time in arteries (Boerth et al., 1997;
Browner et al., 2004). Furthermore, FlincG-loading efficiency is only modest (10-20%)
and transient, since intracellular FlincG is degraded over time by proteases. Thus, future
studies on [cGMP]i dynamics in intact tissue may greatly benefit from the development
of FlincG transgenic mice. This transgenic approach is advantageous over current
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methods, because [cGMP]i dynamics can be studied directly in freshly isolated arteries.
Furthermore, tissue-specific expression of FlincG may reveal distinct cGMP patterns in
various cell types such as vascular smooth muscle, cardiac myocytes or endothelial cells.
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Methods
Protein expression and purification
To express α-FlincG, E.Coli BLR were transformed with α-FlincG-containing pRSET-A
vectors and were cultured at 25°C for 12h after protein induction with 0.4 mM isopropylβ-D-thiogalactoside (IPTG). After centrifugation, α-FlincG was purified using cyclic
nucleotide affinity chromatography as described previously (Feil et al., 1993).

Cross-linking of α-FlincG with TAT and in vitro characterization
To cross-label α-FlincG with TAT, purified protein (0.5 mg/ml) was mixed with a 50fold molar excess of Npys-TAT under nitrogen atmosphere. 200 nM recombinant TATα-FlincG was combined with increasing concentrations of cGMP (0-10 µM) or cAMP (0100 µM) to generate cNMP dose response curves. Excitation spectra (detected at 510 nm)
and emission spectra (excited at 410 or 480 nm) were taken using a fluorescence
spectrophotometer F4500 (Hitachi, Tokyo, Japan).

TAT-α-FlincG in intact cerebral arteries
TAT-α-FlincG (50 µl) was then added to a canulated, pressurized, freshly isolated
anterior, cerebral artery (~80-130um diameter) and incubated 12-15h at 37°C. Imaging
for NO application was performed using the Noran OZ (Middleton, WI) laser scanning
confocal system (10 second acquisitions; 60 x magnification). Epi-fluorescence imaging
was performed to follow 8-Br-cGMP and ANP-evoked cGMP responses (10 sec
acquisitions; 40 x magnification).
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Figure legends:
Figure 1: (A) Non-genetic delivery of TAT-FlincG into intact tissue. Surface accessible
Cys residues of FlincG were labeled with an NPys-activated form of TAT. Following
translocation into VSM cells within intact arteries, the carrier is cleaved and the biosensor
is liberated. (B) cGMP and cAMP selectivity of recombinant TAT-α-FlincG.

Figure 2: Rat cerebral arteries incubated with (A) TAT-α-FlincG and nuclear stain or (B)
without any treatment. Confocal images were taken at 60 x magnification (see Methods).
(C) Application of 50 µM 8-Br-cGMP.

Figure 3: cGMP signaling in intact cerebral arteries upon application of (A) 5 µM DEANO and (B) 100 nM ANP.
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CONCLUSIONS AND FUTURE DIRECTIONS
In this dissertation, we investigated in detail the mechanism of PKG activation
using site-specific mutagenesis, electrospray ionization mass spectrometry, kinase
activity assays, cGMP binding and dissociation studies (chapter two) as well as
crystallography (chapter three). Based on the specific cGMP binding characteristics of
PKG, we developed a new generation of cGMP biosensors to examine the spatial
distribution of [cGMP]i in response to NO and ANP in VSM cells (chapter four) and in
intact tissue (chapter five).
In chapter two, we mutated several conserved aminoacids in the cGMP binding
pockets of PKG regulatory domain to investigate the molecular mechanism of PKG
activation. Based on site A and site B knock-out mutants (G167E, E168G, G291E,
E292G), we suggest an overall concerted mechanism of activation for PKG I α that is
significantly different form the sequential mechanism of PKA activation. Our results
support coupling between both cGMP binding sites A and B, as well as coupling between
cGMP binding site A and the catalytic domain. Furthermore, cGMP binding site B seems
to play a pivotal role in modulating responsiveness of PKG to a broader range of
[cGMP]i. In addition, the structural order of high and low affinity binding sites for PKG I
α have been determined as sites A and B, respectively. We further investigated the roles
of aminoacids arginine 177 and arginine 301, that are highly conserved among protein
kinases, and that coordinate the phosphate backbone of cAMP in PKA (Bubis et al.,
1988; Zawadzki and Taylor, 2004). In contrast, our studies have shown that these highly
conserved arginines are not essential for stabilizing cGMP in PKG. That raises the
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question, what the functional role of the conserved arginine in the cGMP binding pocket
is. It could still be involved in coordinating cGMP, but it might also be the discriminating
factor for distinguishing between cGMP and cAMP binding. In addition to cGMP,
binding and activation assays should be performed for cAMP to test the hypothesis that
the conserved arginine plays a role in cGMP selectivity. PKA-selective inhibitors such as
Rp-cAMPs have been shown to bind to the cAMP binding pocket in a certain steric
conformation (Dostmann and Taylor, 1991). Therefore, the effect of PKG-selective
inhibitors (Rp-cGMPs) on the arginine mutants should be examined. In particular, the
crystal structure of PKG, or the regulatory domain, would be of great benefit to decipher
molecular interactions between cGMP and the cGMP binding pockets and to unravel the
molecular details essential for PKG activation.
In general, crystallization studies require large quantities of protein, in order to
screen as many conditions as possible for successful crystallization. PKG wildtype can
only be expressed in a soluble form in (SF9-) insect cells (Feil et al., 1993), thereby
demanding long expression times (>72 hours) and generally resulting in protein yields (<
5mg/l) too low for crystallization. In chapter three, we developed successfully a bacterial
expression and purification protocol for deletion fragments of the regulatory domain of
PKG, resulting in protein quantities sufficient for crystallization (> 5 mg/ 50 ml). We
attempted to crystallize these deletion fragments of the regulatory cGMP binding domain,
as well as full-length, wildtype PKG utilizing Hampton Screens #1 and #2, and were able
to obtain crystals and crystal-like structures (Figures 3 and 5, chapter 3). These
preliminary crystallization conditions need to be refined in future studies by varying pH,
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incubation temperature, salt- and precipitant concentrations. Fine-tuning these conditions
and utilizing macro- or micro- seeding may result in enlarged PKG crystals that qualify
for high diffraction and ultimately reveal a structural model for PKG. Although crystal
structures will provide invaluable insights into PKG structure and function, they are static
and limited in their use to study the dynamics of PKG in a physiologically-relevant
environment.
To meet this challenge, we developed a new generation of cGMP biosensors
(FlincG) to monitor cGMP signaling in living cells and in intact tissue (Chapters 4 and 5).
FlincG excels in monitoring [cGMP]i in response to physiological (low-nanomolar) NO
concentrations and is suitable for high-resolution, real-time confocal microscopy. FlincG
revealed the differential role of PDE-5 in the modulation of global cGMP in response to
NO donors, and the spatial spread of cGMP away from the cell membrane in response to
ANP. FlincG holds the promise of unraveling the complex interplay between cGMP and
calcium signaling near the cell membrane and should ultimately be suitable for
development of tissue-specific generation of transgenic mice with endogenous cGMP
indicators, as has been done recently for calcium sensing with GCaMP (Ji et al., 2004;
Tallini et al., 2006). One of the most important criteria for developing a transgenic mouse
is the maximal signal-to-noise ratio of the biosensor. For GCaMP, the recombinant
protein displayed 4-fold maximal fluorescence intensity change upon stimulation (Nakai
et al., 2001), but in the transgenic GCaMP-mouse, the change in fluorescence intensity
was decreased to approximately 1.6 fold (Ji et al., 2004; Tallini et al., 2006). GCaMP is
composed of cpEGFP sandwiched between calmodulin and M13. The reduction in
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fluorescence intensity in transgenic mice is most likely due to interactions of calmodulin
and M13 with endogenous proteins. Our FlincG indicators, however, were specifically
designed to prevent interactions with endogenous PKG, by deleting the N-terminal
dimerization domain. Therefore, the overall maximal 1.75 fold increase in fluorescence
intensity should not vary between recombinant δ-FlincG and the biosensor in transgenic
mice. Furthermore, overall signal strength of the biosensor should be verified, by
comparing the basal fluorescence of EGFP-transfected cells with δ-FlincG transfected
cells. This is important, since a very ‘dim’ indicator could not be distinguished from autofluorescent cells in a transgenic mouse.
To study in greater detail the role of compartmentalized cGMP signaling, FlincG
should be fused to the GC-A receptor to co-localize the biosensor to the cell membrane.
Similarly, FlincG can be tethered to phosphodiesterases, G-protein kinase anchoring
proteins, or to cyclic nucleotide gated ion channels to force the biosensor into close
proximity to target molecules and to study cGMP dynamics together with calcium in
spatially distinct compartments in cells. Currently, FlincG offers the exciting possibility
to study calcium and cGMP dynamics simultaneously, by utilizing Fura- or Rhodaminecalcium dyes. To expand the variety of imaging options, cpEGFP in FlincG may be
replaced by other circular permutated fluorophores (e.g. tangerine). The concept of this
new generation of cGMP indicators may also set the stage for the development of nonFRET based cAMP biosensors. This approach holds the exciting potential to investigate
not only the cross-talk between cGMP and calcium, but also between cGMP and cAMP,
by utilizing modified FlincG and FRET-based cAMP indicators simultaneously.
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In the future, FlincG can be used as a tool not only to address physiologically
relevant questions, but also to study the structure and function of PKG. FlincG biosensors
are composed of the regulatory domain of PKG fused to the N-terminus of cpEGFP.
Since FlincG biosensors can be expressed in bacteria and purified to reasonable yield (> 7
mg/l), they are prime candidates for crystallization studies. Screening for FlincG-crystals
should be facilitated by the fact that the presence of green fluorescent protein (GFP)
'stains' the crystals green. Furthermore, the structure-solving process of FlincG should be
fairly straight forward, since the crystal structure of GFP (Ormo et al., 1996) can be
utilized for molecular replacement. The structural characterization would allow us to gain
insight into the regulatory domain of PKG as well as into the folding properties that
define cGMP biosensors. In addition, the overall change in fluorescence intensity of
FlincG can be used as read-out system to screen for novel PKG inhibitors and activators.
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